Increased erythrophagocytosis induces ferroptosis in macrophages and alters the immune response to subsequent stimuli by Youssef, Lyla
Increased erythrophagocytosis induces ferroptosis in 
macrophages and alters the immune response to subsequent 
stimuli 
Lyla Amelia Youssef 
Submitted in partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 














Lyla Amelia Youssef 
All rights reserved 
  
ABSTRACT 
Increased erythrophagocytosis induces ferroptosis in macrophages and alters the immune 
response to subsequent stimuli 
Lyla Amelia Youssef 
 
Red blood cell (RBC) transfusions are associated with adverse effects, such as an 
increased risk of bacterial infection. In preparing RBCs for transfusion, donor RBCs are 
refrigerator stored for extended periods of time, during which they undergo oxidative damage, 
ultimately leading to their rapid post-transfusion clearance from the circulation. Macrophages 
play important roles in recycling iron derived from the clearance of RBCs. They are also a 
critically important component of host defense, protecting against invading pathogens. However, 
the effects on macrophage biology of acutely ingesting large numbers of RBCs are not 
completely understood. To investigate this issue, we used a mouse model of RBC transfusion 
and clearance, which mimics the clinical setting. In this model, transfusions of refrigerator 
storage-damaged (i.e., “old”) RBCs led to increased erythrophagocytosis by splenic red pulp 
macrophages (RPMs). This robust erythrophagocytosis induced ferroptosis, an iron-dependent 
form of cell death, in RPMs. This was accompanied by increases in reactive oxygen species 
and lipid peroxidation in vivo, which were reduced by treatment in vitro with ferrostatin-1, a 
ferroptosis inhibitor.  
Old RBC transfusions also induced RPM-dependent chemokine expression by splenic 
Ly6Chi monocytes, which signaled Ly6Chi monocyte migration from bone marrow to spleen, 
where these cells subsequently differentiated into RPMs. The combination of cell division 
among remaining splenic RPMs, along with the influx of bone marrow-derived Ly6Chi 
monocytes, suggests that, following RPM depletion induced by robust erythrophagocytosis, 
there is a coordinated effort to restore homeostasis of the RPM population by local self-
maintenance and contributions from circulating monocytes.  
However, the effects on the overall functioning of the splenic Ly6Chi monocytes and 
remaining RPMs are unclear, especially their responses to subsequent immune challenges. In a 
mouse model of RBC storage and transfusion, we found that, following a transfusion of old 
RBCs, macrophages were less capable of phagocytosing a subsequent particle stimulus, such 
as bacteria (i.e., Escherichia coli and Staphylococcus aureus) or additional old RBCs. However, 
splenic Ly6Chi monocytes became activated in a specific timeframe following the initial old RBC 
transfusion, thereby increasing their phagocytic capacity. Nonetheless, despite contributions 
from activated splenic Ly6Chi monocytes, RPM function was indispensable for clearing S. 
aureus; this functional impairment may make the transfusion recipient susceptible to S. aureus 
sepsis. In conclusion, these findings may be clinically relevant to pathological conditions that 
can arise as a result of increased erythrophagocytosis, such as transfusion-related 
immunomodulation and impaired host immunity.
i 
TABLE OF CONTENTS 
LIST OF FIGURES  v 
LIST OF TABLES viii 
AKNOWLEDGEMENTS           ix 
DEDICATION           xii 
CHAPTER 1: Introduction 
Section 1.1: Hematopoiesis and red blood cell development 1 
Section 1.1a: Hematopoiesis 1 
Section 1.1b: Erythropoiesis 3 
Section 1.1c: Erythroblastic islands 6           
Section 1.2: Iron recycling  9 
Section 1.2a: Overview   9 
Section 1.2b: Changes to RBCs during senescence   9 
Section 1.2c: Eryptosis 12 
Section 1.3: Iron metabolism by macrophages 13 
Section 1.3a: Iron handling 16 
Section 1.3b: Iron and bacterial infections 17 
Section 1.4: Ferroptosis 20 
Section 1.5: Macrophages and Monocytes 23 
Section 1.5a: Monocytes           23 
Section 1.5b: Macrophages 27 
Section 1.5c: Macrophages in the spleen 27 
Section 1.5d: Macrophage polarization 28 
Section 1.6: RBC Storage 32 
Section 1.6a: The RBC storage lesion 32 
ii 
Section 1.6b: Effects of transfusing storage-damaged RBCs in animal models 
35 
Section 1.6c: Clinical effects of transfusing humans with storage-damaged RBCs            
36 
Section 1.7: Thesis Aims 39 
CHAPTER 2: Materials and Methods      40 
Section 2.1: Mice 40 
Mouse strains 40 
Genotyping Spic KO mice (129S-Spictm1Kmm/J)  42 
Section 2.2: RBC preparation and transfusions 44 
RBC collection 44 
RBC transfusions 44 
Antibody-coating RBCs    44 
Heat-damaged RBCs 45 
Fluorescent labeling of RBCs    45 
Section 2.3: Surface and intracellular staining         45 
Microscopy, immunofluorescence staining  45 
Cell isolation, flow cytometric analysis, and sorting 48 
Annexin V staining 51 
Intracellular staining for Ki67   51 
Lipid peroxidation and ROS studies 51 
Section 2.4: Gene expression analysis 52 
Quantitative reverse-transcriptase PCR 52 
iii 
RNAseq analysis      54 
Section 2.5: Adoptive transfer 54 
Section 2.6: Cell Culture Assays 55 
In vitro erythrophagocytosis assay 55 
High-throughput microscopy assay 55 
In vitro erythrophagocytosis and infection assays 56 
Section 2.7: Bacterial infections 57 
Bacteria 57 
Fluorescently labeling bacteria  57
RBC transfusions and bacterial infections 57 
Section 2.8: Imaging luciferase activity in vivo 58 
Section 2.9: Assessment of RBC recovery and clearance in vivo by flow cytometry      58 
Section 2.10: Statistical analysis 58 
CHAPTER 3: RBC clearance in the spleen 60 
Section 3.1: Introduction 61 
Section 3.2: Results 62 
Section 3.3: Discussion 77 
CHAPTER 4: Increased erythrophagocytosis induces ferroptosis in macrophages          78 
Section 4.1: Introduction   79 
Section 4.2: Results   81 
Section 4.3: Discussion   93 
CHAPTER 5: Splenic Ly6Chi monocytes mediate an inflammatory response to transfused 
RBCs   96 
Section 5.1: Introduction   97 
Section 5.2: Results   99 
iv 
Section 5.3: Discussion 110 
CHAPTER 6: Altered immune response following transfusion 111 
Section 6.1: Introduction 112 
Section 6.2: Results 114 
Section 6.3: Discussion 127 
CHAPTER 7: Conclusion and Future Directions 130 
REFERENCES 137 
APPENDICES 178 
Appendix A: List of Manuscripts 178 
Appendix B: List of Fellowships and Awards 179 
v 
LIST OF FIGURES 
Figure 1.1: Erythropoiesis 5 
Figure 1.2: Erythroblastic islands 8 
Figure 1.3: RBC lifespan 11 
Figure 1.4: Iron metabolism by the macrophage 15 
Figure 1.5: Ferroptosis 22 
Figure 1.6: Monocyte trafficking during inflammation 26 
Figure 1.7: Storage lesion 34 
Figure 2.1: Gating strategy for selecting live, single cells by flow cytometric analysis 50 
Figure 3.1: RPMs are the predominant splenic population that ingests transfused old RBCs    65 
Figure 3.2: Erythrophagocytosis in the spleen occurs shortly after transfusion of old RBCs      66 
Figure 3.4: Ly6Chi monocytes increase expression of several genes responsible for iron 
metabolism following a transfusion of old RBCs 68 
Figure 3.5: RPMs ingest transfused IgG-RBCs and heat-damaged RBCs 69 
Figure 3.6: Transfused old RBCs localize to the marginal zone containing CD169+ and SIGN-
R1+ macrophages 72 
Figure 3.7: VCAM-1+, F4/80hi bone marrow macrophages ingest transfused old RBCs             74 
Figure 3.8: Bone marrow macrophages ingest transfused IgG-coated RBCs and heat-damaged 
RBCs              75 
Figure 3.9: Circulating Ly6Chi monocytes do not ingest old, storage-damaged RBCs 76 
Figure 4.1: RPMs are depleted following a transfusion of old RBCs   83 
Figure 4.2: Transfusions of old RBCs induce oxidative stress and PTGS2 expression in RPMs 
  84 
Figure 4.3: Splenic RPMs exhibit local self-maintenance following old RBC transfusion-induced 
cell death                                                                                                                                      87 
vi 
Figure 4.4: Bone marrow cells cultured in the presence of m-CSF differentiate into a uniform 
VCAM-1+ and F4/80hi population  89 
Figure 4.5: Enhanced erythrophagocytosis induces macrophage ferroptosis in vitro   90 
Figure 4.6: BMDMs are susceptible to cell death after treatment with ferroptosis inducers   92 
Figure 5.1: Ly6Chi monocytes emigrate from the bone marrow and home to the spleen after 
transfusion of old RBCs                                                                                                              100 
Figure 5.2: The increase in splenic Ly6Chi monocytes is not due to cell division of local 
monocytes                                                                                                                                  101 
Figure 5.3: CCL2 and CCL7 mRNA expression by splenic Ly6Chi monocytes following enhanced 
erythrophagocytosis 104 
Figure 5.4: Splenic Ly6Chi monocytes, but not RPMs, express CCL2 105 
Figure 5.5: Ly6Chi monocytes in the blood and bone marrow do not express CCL2 106 
Figure 5.6: CCL2 and CCL7 mRNA expression by splenic Ly6Chi monocytes following enhanced 
erythrophagocytosis requires the presence of RPMs                                                                 107 
Figure 5.7: Ly6Chi monocytes from the circulation contribute to replenishing the depleted RPM 
population in the spleen                                                                                                              109 
Figure 6.1: An initial erythrophagocytosis event in vitro impairs subsequent phagocytosis of IgG-
coated RBCs, S. aureus, and E. coli by macrophages                                                               115 
Figure 6.2: An initial phagocytosis event in vivo involving transfused old RBCs impairs 
phagocytosis by RPMs of a subsequent transfusion of old RBCs or an infusion of S. aureus, but 
not of an infusion of E. coli                                                                                                          117 
Figure 6.3: Ly6Chi monocytes become activated and exhibit increased phagocytosis following an 
initial erythrophagocytosis event in vivo involving the transfusion of old RBCs                           121 
Figure 6.4: Ly6Chi monocytes become activated and alter their gene expression in response to 
S. aureus infection following a transfusion of old RBCs                                                              123 
vii 
Figure 6.5: An initial erythrophagocytosis event in vivo involving the transfusion of old RBCs 
leads to improved circulatory survival of subsequently transfused old RBCs 125 
Figure 6.6: An initial erythrophagocytosis event in vivo involving the transfusion of old RBCs 
leads to impaired clearance of a systemic S. aureus infection 126 
Figure 7.1: Model for ferroptosis induced in macrophages and inflammatory response after a 
transfusion of old RBCs 136 
viii 
LIST OF TABLES 
Table 2.1: List of mouse strains used 41 
Table 2.2: Spic-/- PCR genotyping protocol        43 
Table 2.3: Antibodies used for immunofluorescence microscopy 47 
Table 2.4: Antibodies used for staining surface antigens 49 
Table 2.5: Real time PCR primers 53 
ix 
AKNOWLEDGEMENTS 
My time as a PhD student has been a long and eventful journey in which I’ve been able 
to grow as a scientist and person. Where I stand today would not have been possible without 
the support of numerous people that have been gracious enough to help me. From experiments, 
to conferences, to writing papers, and everything in the between, this has truly been a group 
effort. While this merely serves as a small section in my dissertation, the impact from all of the 
support that I have had is felt beyond that. 
The first person that I’d like to thank is my mentor, Dr. Steven Spitalnik. I came to you to 
see if I could rotate in your lab for the summer. You had never had a PhD graduate student 
before, but you decided to take a chance on me. Throughout my time in your lab you’ve taught 
me a lot and been a tremendous mentor. No matter how busy you were, you always made time 
for me, whether it was questions I had or something random I wanted to share with you. You 
made sure I never felt limited in anyway and you let me explore my interests. I’ve learned a 
tremendous amount from you, both in the field of hematology and immunology, as well as what I 
gain from watching the examples you set with your actions and how you lead. I always gave 
you, and will continue to give you, a hard time about interrupting me. However, underneath it all, 
I think that you played a huge role in helping me find my voice and learning to speak up; which 
will forever be an ongoing process.    
The second person that I owe a tremendous amount of gratitude to is Dr. David Fidock. 
While you’ve served as the chair of my thesis committee, you’ve helped guide me through my 
project and given me wonderful advice. You’re always willing to answer any questions that I 
have. However, much of my gratitude to you extends beyond that role, to your support from 
when I first started the program. I definitely struggled my first year in the program while I was 
rotating and I was having trouble figuring out where I wanted to be. You supported me through 
all of that, when you could have easily not and let me fend for myself. Without your support early 
x 
on, there is a very real chance that I may not have remained in the graduate program prior to 
finding my mentor Dr. Spitalnik. You, in addition to Zaia Sivo, helped connect me with Steve and 
I guess we can say the rest is history.  
To Drs. Jonathan Dworkin and Anthony Ferrante, thank you so much for your willingness 
to serve on my thesis committee, as I’ve benefitted greatly from your insights and ideas. 
Throughout the duration of my progress, it’s extremely evident that you both are invested in me 
succeeding. Tony, you were always so eager to help in any way that you could, whether it was 
providing mice or connecting me with members of your lab who could help with different aspects 
of my project. You even went as far as to include me in your lab meetings, which I really 
enjoyed. Jonathan, you have provided extremely valuable insight into my project, both during 
the committee meetings and outside of them. I also appreciate your willingness to help Steve 
and I when we were looking for guidance regarding some of the experiments we were 
considering. Thank you in advance to Dr. Karina Yazdanbakhsh for agreeing to serve as my 
outside defense committee member, as I am extremely grateful for your willingness to share 
your time. 
Throughout my time at Columbia, I’ve been fortunate enough to make really wonderful 
friends that have helped me through good and bad times. Joe Thome, you were the one of the 
first people that I met at Columbia while I was on my recruiting trip. I always have fun when we 
hang out together and you’ve always been willing to give me guidance when I needed it. Dave 
Corrigan and Melanie Mumau, thank you for your support and the great times we’ve shared. 
Maria Rahmany, you’ve been a tremendous mentor to me and I’m so thankful for the 
opportunities you’ve given me. Jackie Appell, though you’re not at Columbia, I have to thank 
you for being such a wonderful friend and always being there. 
   I’d also like to thank the members of the Laboratory of Transfusion Biology, which I’m 
a part of. Everyone in the lab is always willing to help out or provide insight when needed. Many 
aspects of the experiments that I performed would not have been possible without them. Much 
	 xi 
of my work would also not have been possible without the various core facilities on campus. 
Thank you to the members of the CCTI Flow Cytometry Core, the High-Throughput Screening 
facility at the Columbia Genome Center, and the Small Animal Imaging facility in the HICCC. 
 I’d like to thank my funding sources, the Ruth L. Kirchstein National Research Service 
Award through the National Institute of Health’s (NIH) National Heart, Lung and Blood Institute 
(F31), as well as the T32 NIH Institutional Training Grant through the Department of 
Microbiology and Immunology at Columbia University, which have enabled me to pursue my 
various scientific endeavors during my time here. Thank you so much to all of the support staff 
that helped me submit and process these fellowships, because I wouldn’t have been able to do 
this without you all. I’d like to also give a special thank you Dr. Lis Welniak, for her help with my 
F31 fellowship application, both in terms of guidance and support. 
 Finally, to my parents, Hamid and Dina Youssef, you both have always made me feel as 
though I could do anything and never tried to limit me. From early morning swim practices every 
day during high school to helping me when I’m sick, you both have always been there. I 
definitely don’t take your love and support for granted and I’m thankful to have you both in my 
life. You’ve both helped shape who I am today and I look forward to more adventures together. I 




I’d like to dedicate this dissertation to my mentor, Dr. Steven Spitalnik. You’ve helped me 
grow tremendously and this work would not have been possible without you. Your mentorship 
has extended well beyond the confines of the laboratory and I greatly appreciate the time you’re 
willing to share with me.   
	 1 
CHAPTER 1: Introduction 
 
Section 1.1: Hematopoiesis and red blood cell development 
Section 1.1a: Hematopoiesis 
 Hematopoiesis is an important process by which blood cells are formed. Stem cells that 
reside in the bone marrow are required to replenish the relatively short-lived mature blood cells 
in the circulation. Hematopoietic stem cells (HSCs) are a rare cell population that resides in the 
bone marrow and gives rise to diverse types of blood cell lineages through the production of 
various progenitor cell populations.(1) HSCs are capable of differentiation and self-renewal; the 
latter produces additional HSCs. The unique feature that defines HSCs is their ability, through 
differentiation, to reconstitute the entire blood system of a recipient.(2, 3)  
 During vertebrate development, blood cells develop due to waves of hematopoietic 
activity at different anatomical sites.(4) These sites in mammals include the yolk sac, the aorta-
gonad mesonephros (AGM) region, the fetal liver, and the bone marrow. The development of 
cells in the blood occurs in at least two waves of hematopoietic development. The first occurs 
within the yolk sac and is referred to as the “primitive” wave. The primitive wave produces cells 
such as RBCs that are needed to oxygenate tissues during embryonic development. The 
second wave of hematopoiesis is termed “definitive” or “adult” hematopoiesis and occurs in the 
embryo.(5) More specifically, the second wave of hematopoiesis can occur in the AGM 
region.(6–10)  
 One important aspect of the development of HSCs is their microenvironment, or niche, 
which influences the regulation of differentiation and self-renewal. The regulatory signals in the 
niche can arise from surrounding cells, including bound or secreted molecules, as well as 
physical cues such as oxygen tension, shear stress, and contractile forces.(11–14) One of the 
commonly studied sites of HSC differentiation is the bone marrow and several studies offer 
insight into the bone marrow niche. Various cell types are involved in HSC maintenance as part 
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of the niche. These include perivascular stromal cells, endothelial cells, macrophages, CXCL12-
abundant reticular cells, sympathetic neurons, and nonmyelinating Schwann cells.(15–22) 
Some of the established soluble regulators of HSC development included CXCL12, SCF, 
pleiotrophin, angiopoietin 1 (ANGPT1), and TGF-β.(18, 21, 23–25) (Figure 1.2) 
Studies in mice led to the subdivision of HSCs into three populations, arranged by a 
progressive loss in their ability to self-renew. These are long-term HSCs, which can self-renew 
virtually for life,(2, 26, 27) short-term HSC populations, which have a limited self-renewal 
capacity, and multipotent (e.g., lymphomyeloid) progenitors, which do not self-renew.(27, 28) An 
additional characteristic of HSCs that affects their developmental potential includes sequential 
activation or silencing of various genes that lead to the irreversible restriction of select lineage 
commitments. In addition to the loss of self-renewal activity, the coordinated changes of 
developmental potential of HSCs also include the irreversible restriction to one or more lineage 
commitments, owing to sequential activation or silencing of various genes.(29, 30) Depending 
on the various signals and gene expression patterns, multi-potent progenitors can give rise to 
various cells, including common lymphoid progenitors (CLP) and common myeloid progenitors 
(CMP). CLPs can then further differentiate into various lymphoid cells, such as B cells, T cells, 
and NK cells. CMPs differentiate into granulocyte-macrophage progenitors (GMPs) or 





Section 1.1b: Erythropoiesis 
 During the first, primitive wave of hematopoiesis, primitive erythroid cells (EryP) are 
produced in the yolk sac.(31–33) These EryP cells give rise to large, nucleated erythroid cells 
during this wave. These blast-like cells retain their nuclei until mid-gestation.(34–36) The 
primitive wave of erythropoiesis is transient, but the terminally differentiated cells that are 
produced persist through the end of gestation. EryP cells exhibit specific gene switching within 
the β-globin locus (37), which involves subsequent changes in expression from embryonic to 
adult hemoglobin. In addition to this, EryP cells also differ in the cytokines and transcription 
factors that they require. Finally, EryP cells arise from mesodermal progenitors and can be 
identified within blood islands in the yolk sac. 
As development proceeds, EryP cells are replaced by the rapidly expanding population 
of definitive erythroid cells (EryD).(35, 36) The most immature definitive erythroid progenitor is 
the burst-forming unit erythroid (BFU-E). BFU-E cells continue to divide and eventually 
differentiate into the colony-forming unit erythroid (CFU-E).(38) CFU-E cells rapidly divide and 
continue to differentiate. Erythropoietin (Epo) is a kidney-derived cytokine that regulates 
erythropoiesis; it also stimulates the terminal proliferation and differentiation of CFU-E 
progenitors under hypoxic conditions. These early stages of erythropoiesis are highly Epo 
dependent, whereas later stages no longer depend on Epo (39–41); indeed, cellular Epo 
receptors (EpoR) are gradually lost as erythroid progenitors differentiate.(42) Aside from Epo, 
BFU-E cells also respond to insulin-like growth factor 1, glucocorticoids, IL-3, and IL-6. 
Activation of intracellular signaling pathways is also important during erythropoiesis. 
Signal transducer and activator of transcription 5 (Stat5), phosphoinositide-3 kinase/Akt, and 
Shc/Ras/mitogen-activated kinase (MAPK) pathways are activated by binding of Epo to EpoR. 
These Epo-regulated transcriptional regulators interact with select lineage-restricted 
transcriptional regulators for erythropoiesis, such as GATA-1, SCL/Tal1, LMO2, LDB1, Klf1, and 
Gfi-1b.(43, 44)  
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Development from the pro-erythroblast to the reticulocyte involves 4-5 rapid cell 
divisions, resulting in a progressive reduction in cell size. Maturation from erythroid-committed 
precursors is called terminal erythropoiesis and occurs in the bone marrow within erythroblastic 
islands, which consist of a central macrophage surrounded by erythroblasts, and ends in the 
blood stream, where reticulocytes complete their maturation within 1–2 days. During this phase, 
proerythroblasts undergo morphological changes, such as cell size reduction and chromatin 
condensation, produce specific proteins, such as hemoglobin, and exhibit a reduced 
proliferative capacity to give rise successively to basophilic, polychromatophilic, and 
orthochromatophilic erythroblasts. As this progresses to terminal differentiation, there is 
complete repression of all gene transcription, chromatin condensation, nuclear condensation, 





Figure 1.1: Erythropoiesis 
Overview of erythropoiesis. Within the bone marrow, HSCs can differentiate and undergo 
maturation to become RBCs, with several intermediate stages.  
  








Section 1.1c: Erythroblastic islands 
Adult erythropoiesis takes place in the bone marrow, with terminal erythrocyte 
differentiation occurring in erythroblastic islands. Erythroblastic islands are specialized 
structures consisting of a macrophage surrounded by developing erythroblasts, which creates a 
specialized microenvironment.(45, 46) (Fig 1.5) The macrophage, referred to as a nurse 
macrophage, participates in erythroid development by providing iron for heme synthesis. The 
macrophages in the erythroblastic islands also ingest the nuclei that have been expelled from 
the erythroblasts during terminal erythroid differentiation (i.e., “enucleation”).(47, 48) The 
macrophages and erythroblasts have adhesion molecules to help retain the expelled nucleus on 
the surface of the macrophage before it is phagocytosed. For example, erythroblast 
macrophage protein (Emp) (49) and β1 integrin (50) are distributed on the nucleus after 
expulsion to help maintain the interaction between the nucleus and the macrophage. 
In addition, nurse macrophages stimulate proliferation and survival of erythroblasts.(51) 
During this interaction, ferritin is released by macrophages via exocytosis and internalized by 
erythroblasts by endocytosis, where it is processed to produce heme.(52) Emp promotes 
binding between the macrophage and the erythroblast, and is present on the surface of both cell 
types.(50) Indeed, this interaction between macrophage and erythroblast is essential for 
erythropoiesis.(49, 53) Another important molecular interaction in erythroblastic islands occurs 
between the α4β1 integrin (Very Late Antigen 4; VLA-4) on erythroblasts and vascular cell 
adhesion molecule 1 (VCAM-1) on macrophages.(54) Intercellular adhesion molecule 4 (ICAM-
4) is expressed on erythroblasts and αV integrin present on macrophages help maintain island 
integrity. For example, if binding between ICAM-4 and αV integrin is disrupted, a diminished 
number of erythroblastic islands are found.(54) CD163, a hemoglobin-haptoglobin complex 
scavenger (55), is another macrophage receptor that interacts with erythroblasts.(56) In addition 
to being able to clear free hemoglobin from the circulation, CD163 contains an erythroblast 
adhesion motif to mediate the binding of macrophages to erythroid precursors.(56) 
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Soluble factors, secreted by both erythroblasts and macrophages, also play important 
roles in erythropoiesis. These include cytokines, chemokines, and interleukins. As examples, 
TNF-α, TGF-β, IL-6, IFN-γ, and TRAIL are negative regulators of erythropoiesis that are 
released by the nurse macrophage, although erythroblasts can also release TRAIL as a 
negative regulator.(46, 57, 58) In contrast, Gas-6, VEGF-A, and PDGF are positive regulators 






Figure 1.2: Erythroblastic islands 
In the niche where erythropoiesis occurs, nurse macrophages provide iron for 
developing erythroblasts and phagocytose expelled nuclei by the erythroblasts, forming 














Section 1.2: Iron recycling  
Section 1.2a: Overview 
 After RBCs are produced in the bone marrow, they enter the circulation as reticulocytes, 
where they rapidly mature into mature RBCs, which then circulate for approximately 120 days in 
humans. Thus, under steady state conditions in humans, ~1% of erythrocytes are cleared every 
day and replaced by new cells. The circulatory lifespan of murine RBCs is ~45-58 days 
depending on the nature of the inbred strain.(61, 62) While circulating, RBCs pass through the 
liver and spleen numerous times, where they have the opportunity to interact with various 
immune cells, such as macrophages. As the RBCs interact with macrophages, the latter are 
able to examine and probe and interrogate the RBCs, so to speak. In this way, macrophages 
can remove RBCs from the circulation that are damaged or have undergone senescence.(63) In 
the spleen, in particular, RPMs perform these specific functions.   
 
Section 1.2b: Changes to RBCs during senescence  
 Currently, it is not known exactly how RPMs identify circulating damaged or senescent 
RBCs. One possible mechanism for senescent RBC clearance involves Band 3, a 
transmembrane protein that is a potential target for naturally-occurring IgG antibodies, which 
could help facilitate clearance of these RBCs.(64–67) The extracellular domain of Band 3 is 
recognized by the naturally occurring antibodies, whereas the cytoplasmic domain helps 
regulate RBC structure and function.(64, 68, 69) However, it is not completely clear what leads 
to the formation of Band 3 clusters on the surface of RBCs as targets for these antibodies. 
Nonetheless, clustering of Band 3 is found in senescent RBCs that have an increased 
proportion of methemoglobin (MetHb), reduced NADH-reductase activity, and accumulated 
oxidative membrane damage.(70) Furthermore, membrane peroxidation and MetHb are needed 
for Band 3 cluster formation.(70)   
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 Another feature of the immune system that can aid Band 3-clustering in clearing 
senescent RBCs is activation of the classical pathway of the complement system. Thus, the 
naturally-occurring antibodies that bind to Band 3 generate C3b-IgG complexes when active 
complement is present.(71, 72) With this added activation of the complement pathway, 
phagocytosis by macrophages can be enhanced, in contrast to relying only on Fc-receptor-
mediated clearance of IgG bound to Band 3 clusters. These complexes between anti-Band 3 
antibodies are recognized by complement receptor 1 (CR1) and CR3 on the macrophage. While 
this is the current dogma that is prevalent in the field, there is some controversy surrounding 
whether antibodies are required for clearing senescent RBCs.(73)   
 Phosphatidylserine (PS) exposure on the RBC surface is also a potential marker of 
senescence. Thus PS exposure increases on the surface of RBCs as they age(74); this also 
occurs progressively during RBC storage.(75) Possible mechanisms for PS exposure include 
activation of scramblase activity, leading to a loss of phospholipid asymmetry.(76–78) This PS 
exposure is also an important “eat me” signal for macrophages to ingest apoptotic cells.(74, 79)  
 Another potential indicator of RBC senescence is the loss of CD47 from the RBC 
surface. CD47 is a “marker of self” and phagocytosis by macrophages of CD47-expressing cells 
can be prevented through the immunoreceptor signal regulatory protein alpha (SIRP-alpha), 
which is expressed on macrophages.(80, 81) This leads to a SIRP-alpha-CD47 interaction that 
functions as a negative signal for erythrophagocytosis (i.e., “don’t eat me”). Some studies found 
that CD47 decreases occur as RBCs age in vivo and are stored in vitro.(82, 83)(84) However, 
CD47 is also a potential “eat me” signal; thus, CD47 on aged erythrocytes underwent a 
conformational change, inducing CD47 interactions with thrombospondin-1 (TSP-1) as a 





Figure 1.3: RBC lifespan 
RBCs are generated in the bone marrow and then released into the circulation, following 
erythropoiesis. Once in the circulation, human RBCs have an average lifespan of 120 days. As 
RBCs become senescent, they are cleared by macrophages in the liver and spleen. Once 
internalized, the phagocytes process the RBCs and aid in iron recycling. A portion of the iron 
from the ingested RBCs is exported, via ferroportin, and bound to circulating transferrin. 


















Section 1.2c: Eryptosis 
 While in circulation, RBCs are exposed to various stressors, such as osmotic shock, 
oxidative stress, and challenges to their structural integrity. Because RBCs do not contain a 
nucleus or mitochondria, they lack the crucial mechanisms required for apoptosis. However, 
stress can induce certain characteristics that are typically associated with apoptosis, such as PS 
exposure on the RBC surface. Therefore, to distinguish this from apoptosis, which occurs in 
nucleated cells, the term “eryptosis” is used to describe this type of cell death in RBCs.(78) 
 Energy depletion impairs the replenishment of reduced glutathione, an essential 
antioxidant needed to prevent oxidative damage.(86, 87) Osmotic shock or oxidative stress can 
trigger Ca2+ uptake by erythrocytes. Increases in Ca2+ can stimulate the activity of scramblase, 
leading to increases in PS exposure on the surface of the RBCs and decreases in phospholipid 
asymmetry.(88) Furthermore, increases in Ca2+ concentrations are seen as RBCs age.(89, 90) 
Prostaglandins, such as prostaglandin E2 (PGE2), stimulate eryptosis by activating cation 
channels in RBCs to increase the cytosolic Ca2+ concentrations.(91–93) This leads to increases 
in PS exposure on the cell surface.(93) The influx of Ca2+ also leads to stimulation of K+ 
channels, resulting in cell shrinkage.(94–97) Therefore, K+ loss from RBCs is capable of 
inducing eryptosis. Cell shrinkage also induces release of platelet activating factor (PAF), a 
phospholipid mediator,(98–103) which stimulates sphingomyelin breakdown and the release of 
ceramide from RBCs.(104) Additionally, PAF induces cell shrinkage and PS exposure. Cell 
shrinkage, as a result of osmotic shock, activates sphingomyelinase, which can then form 
ceramide to sensitize scramblase to the effects of changes in Ca2+ concentration.(78, 105) As 
one possibility, these mechanisms normally prevent the rupture of damaged or aged RBCs, 




Section 1.3: Iron metabolism by macrophages 
 Hemoglobin accounts for the largest pool of heme and iron in mammals.(106) Release 
of large amounts of heme into the circulation by RBC lysis can prove dangerous, because it 
leads to dramatic increases in the amount of circulating iron. To prevent the release of iron from 
damaged or senescent RBCs, macrophages function in the essential role of 
erythrophagocytosis of circulating RBCs. These erythrophagocytic macrophages, such as 
RPMs, ingest senescent or damaged RBCs and recycle their iron for subsequent erythropoiesis.  
 While the RBCs are ingested and processed, heme is released intracellularly from the 
catabolized hemoglobin. This heme is then translocated from the phagolysosome to the 
cytoplasm with the help of the heme responsive gene-1 (HRG1) transporter.(107, 108) As heme 
accumulates in the cytoplasm, heme-responsive genes and proteins are expressed. These 
include heme oxygenase-1 (HO-1), a heme-catabolizing enzyme that catalyzes the first and 
rate-limiting step in heme degradation. HO-1 converts heme into carbon monoxide, free iron, 
and biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. The iron 
is derived from heme can ultimately be released from the macrophage through ferroportin-1 
(FPN1), a transmembrane protein encoded by the solute carrier family 40 member 1 (SLC40A1) 
gene.(109, 110) Alternatively, iron can be stored within the cell in ferritin, a protein composed 
heavy and light chains, (FTH and FTL, respectively). Ferritin contains ferroxidase activity that 
enables it to convert reactive iron (Fe2+) into Fe3+, which is the storage form of iron.  
 Ferritin expression is regulated by various transcription factors, including nuclear 
transcription factor kappa B (NFκB). NFκB upregulates FTH to aid in sequestering iron, thereby 
preventing the generation of reactive oxygen species (ROS), and controlling the subsequent 
activation of the c-Jun N-terminal kinase (JNK) cascade.(111) Nuclear factor erythroid 2–related 
factor 2 (Nrf2), a basic leucine zipper protein that regulates antioxidant proteins, also 
upregulates ferritin expression, with the FTH gene identified as one of the direct target genes of 
Nrf2.(112, 113) Repression of ferritin expression can occur through the presence of CNC 
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homology 1 basic leucine zipper transcription factor 1 (Bach1).(114, 115) Heme is able to 
reverse repression by binding to Bach1, thereby preventing DNA binding and facilitating binding 
of Nrf2.(115, 116) Additionally, heme can inactivate Bach1 by inducing nuclear export (117) and 
polyubiquitination for proteasome-mediated degradation.(118) 
 The genes for the ferritin heavy and light chains both contain heme-responsive maf 
recognition/antioxidant response element (MARE/ARE) promoter sequences.(119, 120) IRP1 
and IRP2 regulate the expression of ferritin by binding to iron responsive elements (IRE) in the 
mRNAs.(121–123) When IRP1 or IRP2 (iron-responsive element-binding proteins) are bound to 
the mRNA, eukaryotic initiation factor 4F has limited ability to recruit translational machinery, 
leading to repressed translation.(124) Subsequently, the presence of heme leads to increases in 
ferritin expression by preventing the binding of IRP1 and IRP2 to the IRE.(125–127) Ftl and Fth 
also have MARE/ARE sequences in their promoters and the IRE in their mRNA 5’-untranslated 
regions, which are distinct heme-responsive elements (128), enabling them to respond 
synergistically.  
  However, during iron deficiency, iron can be liberated from ferritin through a process 
known as ferritinophagy.(128) For this purpose, nuclear receptor coactivator 4 (NCOA4), a 
selective cargo receptor for autophagic turnover of ferritin, is required for delivering ferritin to 







Figure 1.4: Iron metabolism by the macrophage 
RBCs that undergo erythrophagocytosis are processed in the phagolysosome. Within 
the phagolysosome, heme is released from hemoglobin. The heme is then transported to the 
cytoplasm through the heme transporter HRG1 and is catabolized by HO-1 to release iron, as 
well as CO and biliverdin. The iron can then be either released from the cell through ferroportin 
or stored, intracellularly, by ferritin. A small portion of free, unbound iron remains in the 
macrophage as a labile iron pool.   























Section 1.3a: Iron handling 
Adapted from: Youssef LA, Spitalnik SL. Iron: a double-edged sword. Transfusion. 2017 
Oct;57(10):2293-2297.  
Given the ease and rapidity with which iron interconverts between ferrous and ferric 
forms, it plays key roles in redox reactions and, therefore, has important functions in many 
diverse proteins. For example, in addition to its role in oxygen delivery by hemoglobin (Hb) and 
myoglobin, it functions in the reaction centers of multiple enzymes found throughout the body, 
including in the immune system. However, iron's redox biology can also produce damage; for 
example, “free” iron produces reactive oxygen species in the Fenton reaction, which cause 
oxidative stress and harm host tissues by oxidative damage of proteins, lipids, and nucleic 
acids. Thus, because iron behaves as a two-edged sword, tight regulation of its availability and 
biological accessibility is critically important. To this end, multiple chaperones and iron-binding 
molecules prevent adverse redox effects by minimizing the availability of “free” iron. For 
example, transferrin, the primary iron-binding and iron-transport protein in the circulation, has an 
incredibly high affinity constant for iron. In addition, under normal conditions, an excess of non-
liganded transferrin circulates (i.e., transferrin saturation is normally <30%); in this way, when 
“free” iron appears in the circulation, it rapidly binds to transferrin, thereby preventing its 
participation in redox reactions. Only when transferrin is almost fully saturated does non-
transferrin-bound iron appear, which can induce multiple pathologic consequences.(129) 
Analogously, ferritin, the primary iron-binding and iron-storage protein inside cells, helps 
maintain low levels of “free” cytosolic iron. Thus, although the human body contains 3 to 4 g of 
iron (mostly in Hb), only vanishingly small concentrations of free, non-protein-bound iron are 
available under normal circumstances. 
From a research standpoint, we are currently in a “golden age” of iron biology.(130) Over 
the past decade or so, many molecules relevant for iron metabolism were identified and their 
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mechanisms continue to be elucidated. These include, but are not limited to, haptoglobin and its 
receptor CD163, hemopexin and its receptor CD91, hepcidin, ferroportin, erythroferrone, human 
hemochromatosis protein (HFE), hemojuvelin, Steap family proteins, ZIP14, natural resistance-
associated macrophage protein-1, divalent metal transporter-1, and lipocalin-2.(130) These 
discoveries suggested novel therapeutic interventions, pinpointed the genetic underpinnings of 
multiple human disorders, and provided new tools for further investigation of humans and 
animal models. Similarly, there has been an explosion of new knowledge and new tools relevant 
to understanding iron metabolism in microorganisms.(131, 132) 
Of course, iron has a prominent place in transfusion medicine based on its role in Hb 
function. In addition, there are active ongoing discussions about iron deficiency in volunteer 
blood donors, whether it is medically important, and whether steps should be taken to avoid 
it.(133) There is also active discussion regarding whether non-transferrin-bound iron appears 
after stored RBC transfusions and whether it causes clinically relevant adverse outcomes.(134)  
 
Section 1.3b: Iron and bacterial infections 
To put the potential risks of non-transferrin-bound iron into a broader context and explain 
the concerns regarding infectious diseases, a short discussion about nutritional immunity is 
warranted, with a specific focus on iron. Nutritional immunity is a process by which a host 
organism sequesters trace nutrients, such as iron, in an effort to limit infection. The resulting 
decline in freely available iron starves the invading pathogens. Thus, vertebrates can sequester 
iron within cells and in circulating iron-binding proteins, making it an important defense 
mechanism against both intracellular and extracellular pathogens.(132, 135–137) In addition to 
its important role in cooperating with innate immunity, nutritional immunity can also modulate 
adaptive immune responses; indeed, both iron deficiency and iron overload affect cellular 
immunity.(138, 139) 
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In relationship to mammalian hosts, various microorganisms behave as commensal 
“parasites” (i.e., the microbiome) or as pathogens. Some microbes are only commensals (e.g., 
Lactobacilli) or pathogens (e.g., rabies virus), whereas others, which are typically considered to 
be commensal, can also be pathogenic under the right conditions (e.g., Staphylococcus 
epidermidis in the setting of iron overload).(140) Thus, there is a delicate balance and interplay 
between the host and invading microbes. Because iron is existentially important for virtually all 
living organisms, with both benefits and drawbacks, there is fierce competition for iron between 
the host and the commensal/pathogen. To this end, multiple mechanisms allow the host to 
“withhold” iron from the pathogen, both intracellularly and extracellularly. For example, 
inflammatory responses can produce interleukin-6, which induces hepcidin production. Hepcidin 
then down regulates ferroportin expression, thereby decreasing gastrointestinal iron absorption 
and increasing iron retention by macrophages, resulting in iron being withheld from extracellular 
pathogens (e.g., in Staphylococcus aureus sepsis). Unsaturated transferrin, which binds free 
iron in the circulation and subsequently delivers it to cells for storage in ferritin, also limits iron's 
availability to extracellular pathogens. 
Taken together, given the complexity of mammalian and prokaryotic iron metabolism 
and biology, it is difficult to make generalized statements, and more nuanced conclusions are 
frequently required. One example is the distinction between extracellular pathogens (e.g., S. 
aureus) and those adapted to intracellular life (e.g., Salmonella typhimurium).(140, 141) To this 
end, iron-withholding mechanisms that protect the host from S. aureus infection, by increasing 
macrophage iron retention and inducing a state of hypoferremia, can thereby enhance the 
virulence of S. typhimurium, which preferentially infects macrophages.(142) Therefore, the 
protective nature of nutritional immunity for one pathogen can put the host at extreme risk for 
another pathogen. 
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In contrast, multiple mechanisms allow pathogens to adapt and obtain the iron 
necessary for their growth and metabolism, even in “hostile” environments. For example, 
bacteria can “go fishing” by secreting siderophores, which are small molecules that chelate iron 
with high affinity, to extract and capture iron from the host.(131, 132, 137) In particular, 
abundant literature describes iron acquisition mechanisms by S. aureus and iron-withholding 
strategies by the host during infection by this pathogen.(131) 
A related issue involves the concept of ferrophilic and non-ferrophilic microbes; that is, 
although iron is very important, the ability of some organisms to survive and thrive depends 
more critically on adequate iron availability, as compared to others. In addition, some pathogens 
adapt better to iron-withholding environments than others. The most extreme example of this 
phenomenon is a non-ferrophilic pathogen, Borrelia burgdorferi, the etiologic agent of Lyme 
disease, which is one of the very few organisms, along with Lactobacillus, that does not require 
iron at all;(143) therefore, “extra” iron availability would not enhance this pathogen's virulence 
per se. 
In addition, different outcomes result from different methods of iron delivery, different 
pathways to iron overload, and different cell type specificities of iron overload. That is, in many 
studies, different types of iron overload predisposed patients to different types of infection. Thus, 
patients with chronic iron overload due to transfusion-induced hemosiderosis experience 
specific infections, such as Salmonella-induced osteomyelitis in sickle cell disease patients and 
related infections in thalassemia patients.(144–146) Analogously, Yersinia infections are 
classically seen in hereditary hemochromatosis.(147) In contrast, acute iron “toxicity,” such as 
after iron supplementation in humans (148–150) or after stored RBC transfusions in animal 
models,(129, 151) enhances different types of infection depending on whether excess iron is 
delivered intracellularly to macrophages or circulates extracellularly as non-transferrin-bound 
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iron. Finally, concepts regarding nutritional immunity and infection are not limited to bacterial 
pathogens, but are also relevant to mycobacteria, fungi, viruses, and parasites.(132, 136, 147)  
 
Section 1.4: Ferroptosis 
On the topic of the risks of excess iron, it is relevant to discuss ferroptosis, an iron-
dependent non-apoptotic form of regulated cell death.(152) Ferroptosis results from lethal lipid 
peroxidation that occurs in the presence of iron. Therefore, ferroptosis can be suppressed 
through administration of iron chelators, lipophilic antioxidants, and inhibitors of lipid 
peroxidation.(153) The toxic lipid peroxides can be generated in multiple locations within cells. 
Thus, in addition to the plasma membrane, the endoplasmic reticulum and lysosomes are also 
possible locations. Nonetheless, although mitochondria represent one such location, 
mitochondrial lipid peroxidation is not necessary to induce ferroptosis.(154) Possible causes for 
lipid peroxidation include oxidative damage to polyunsaturated-fatty-acid-containing 
phospholipids (PUFA-PLs) through the free-radical reaction involving Fenton chemistry and 
enzymatic processes, such as those involving lipoxygenases (LOXs). LOXs are iron-containing 
enzymes capable of catalyzing the deoxygenation of PUFAs in lipids, leading lipid peroxidation. 
Under steady-state conditions, the intracellular iron concentration is regulated by iron-binding 
proteins and cofactors. However, some intracellular iron exists in low-affinity complexes, 
creating a pool of “labile iron.”(155) This labile iron pool is a likely source for Fenton chemistry, 
which generates hydroxyl and peroxyl radicals, even under steady-state conditions.(156)  
Ferroptosis is found in various diseases. For example, ferroptosis inhibitors prevent the 
synchronized death of renal tubules and oxalate crystal-induced acute kidney injury.(157) 
Ferroptosis is also important in Huntington disease(158), periventricular leukomalacia(158), and 
cancer.(152)   
 To date, four different ways of initiating ferroptosis have been discovered; all linked to 
loss of the activity of glutathione peroxidase 4 (GPX4).(156) GPX4 is an enzyme that removes 
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products of iron-dependent lipid peroxidation to repair the oxidative damage to membranes. 
One way to initiate ferroptosis is through inhibiting system xc-, which is a transmembrane 
cystine-glutamate antiporter.(152) Through inhibiting system xc-, cysteine is depleted from cells, 
leading to impaired antioxidant defenses, because cysteine is needed for producing glutathione 
(GSH), which in turn, is needed for the lipid repair function of GPX4. Erastin, imidazole ketone 
erastin (IKE), and sorafenib are small molecule ferroptosis inducers that target system xc-. 
Ferroptosis can also be induced by directly targeting GPX4. RAS-selective lethal 3 (RSL3) is an 
example of this second type of ferroptosis inducer. RSL3 covalently interacts with the 
nucleophilic active-site of GPX4 to inhibit its enzymatic activity. This results in a loss of the lipid 
repair function, leading to the accumulation of lethal lipid peroxides and eventual cell 
death.(159) A third type of ferroptosis inducer depletes GPX4 from cells as well mevalonate-
derived coenzyme Q10 (CoQ10). CoQ10 acts as an endogenous lipophilic antioxidant in addition 
to its role in the mitochondrial electron transport chain;(160) ferroptosis inducer 56 (FIN56) 
functions via this mechanism. A fourth type oxidizes iron, thereby indirectly inactivating GPX4, 
leading to lipid peroxidation; ferroptosis inducer endoperoxide (FINO2) functions in this 
manner.(161, 162) 
 Inhibition of ferroptosis can be accomplished through various ways. One example is the 
iron chelators, such as defroxamine, which prevent the initiation of lipid peroxidation by 
preventing free radicals formation through the Fenton reaction. Another example is lipophilic 
antioxidants, such as α-tocopherol (a component of vitamin E), butylated hydroxytoluene (BHT), 
and ferrostatin-1 (Fer-1). Lipophilic antioxidants may inhibit ferroptosis by trapping free radicals 
to prevent lipid peroxidation.(163) Deuterated PUFAs (D-PUFAs), another type of inhibitor, likely 
act by preventing the initiation of lipid peroxidation. Because PUFA-PLs are the lipids most 
susceptible to peroxidation, the addition of PUFA-PLs could also mitigate cell death. Finally LOX 







Figure 1.5: Ferroptosis 
Overview of ferroptosis, an iron-dependent form of cell death. Abundant intracellular iron 
present in a cell can lead to the formation of hydroxyl radicals through the Fenton reaction. The 
hydroxyl radicals convert polyunsaturated fatty acids being into lipid hydroperoxides, which can 
cause lipid peroxidation, and ultimately, ferroptosis. Glutathione peroxidase 4 (GPX4) is a vital 
enzyme responsible for neutralizing lipid hydroperoxides, thereby preventing lipid peroxidation. 
GPX4 activity depends on the presence of glutathione, which can be generated through system 
























Section 1.5: Macrophages and Monocytes 
Section 1.5a: Monocytes 
 Monocytes originate through differentiation from definitive hematopoietic stem cells, 
including the monocyte-macrophage dendritic cell progenitor (MDP).(164) Ly6C+ monocyte-
specific progenitors, which are downstream of MDPs, were identified in the bone marrow and 
spleen.(165) Current classifications describe two subsets of monocytes: (1) classical, 
inflammatory Ly6Chi monocytes, which appear to descend directly from Ly6C+ monocyte 
progenitors, and (2) Ly6Clo patrolling, non-classical monocytes, which differentiate from Ly6Chi 
monocytes through an Nr4a1-dependent transcriptional program(165–167) Patrolling 
monocytes function within the vasculature, where they “crawl” over the endothelium in a manner 
dependent upon the LFA-1 integrin.(168) Through this action, patrolling monocytes clear 
damaged endothelial cells to aid in maintaining vasculature integrity.(169) In mice, patrolling 
monocytes express high levels of the CX3C-chemokine receptor 1 (CX3CR1) and low levels of 
the CC-chemokine receptor 2 (CCR2).(170, 171) In addition to expressing high levels of Ly6C 
and CD11b in mice, inflammatory monocytes also express high levels of CCR2, but low levels 
of CX3CR1.(170, 171) 
 Human monocytes are divided into subsets on the basis of surface CD14 and CD16 
expression.(172) CD14++CD16− monocytes (classical monocytes) also express CCR2 and are 
the most prevalent monocyte subset in human blood.(173) The CD16+ monocyte population 
consists of two subsets: CD14+CD16++ (non-classical) and CD14++CD16+ (intermediate) 
monocytes.(173) The CD14+CD16++ subset exhibits patrolling behavior in vivo, making it similar 
to the mouse Ly6Clo monocyte population.(174) Although the monocyte subsets identified in 
humans and mice do not precisely overlap, their differentiation and contribution to immune 
defense appear to have many similarities.(175–177) 
Although monocytes originate in the bone marrow, they are able to leave the bone 
marrow and enter the bloodstream, enabling them to reach peripheral tissues.(178) Monocyte 
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trafficking can occur during homeostasis and inflammation. Once monocytes arrive at select 
sites, they differentiate in macrophage or dendritic cell (DC) populations, following conditioning 
by local growth factors, pro-inflammatory cytokines, and microbial products.(178) As a result, 
monocyte recruitment is essential to the immune system’s ability to clear bacterial, viral, and 
protozoal infections effectively. Monocytes that have egressed from the bone marrow and 
entered the circulation can also return to the bone marrow in the absence of peripheral 
inflammation or emigration signals.  
CC-chemokine ligand 2 (CCL2; also known as MCP1) and CCL7 (also known as MCP3) 
are two important chemokines that bind to CCR2 and mediate Ly6Chi monocyte 
recruitment.(179) Several cell types are capable of expressing CCL2 in response to certain 
types of stimulation or activation by pro-inflammatory cytokines.(179–183) One possible 
mechanism for how CCL2 induces migration of CCR2-expressing cells is that circulating CCL2 
associates with glycosaminoglycans in specific tissues and establishes gradients that guide 
monocytes towards sites of infection or inflammation. To support this possibility, monocyte 
recruitment is impaired by amino acid substitutions in CCL2 that prevent dimerization or 
association with glycosaminoglycans.(184, 185) Another important chemokine for Ly6Chi 
monocyte trafficking is CCL7, which is induced in bacterial infections, leading to monocyte 
migration.(179, 186) The importance of CCL2 and CCL7 in monocyte recruitment is further 
highlighted by the observation that deletion of either CCL2 or CCL7 leads to dramatic decreases 
in monocyte recruitment.(186) 
One function of CCR2 for monocytes is in mediating their emigration out of the bone 
marrow and into the circulation. Thus, CCR2 on the surface of monocytes appears to act as a 
scavenger for CCL2.(187) The surface-expressed CCR2 was internalized with the bound 
chemoattractant (CCL2), but was able to cycle rapidly back to the plasma membrane.(187) In 
addition, following relocation of the source of chemoattractant, monocytes could rapidly reverse 
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their polarization axis to generate a new leading edge along the newly formed gradient, 








Figure 1.6: Monocyte trafficking during inflammation 
 Monocyte trafficking during inflammation. Signals, including chemokines CCL2 and 
CCL7, interact with CCR2 on the surface of Ly6Chi monocytes. Binding of CCL2 and CCL7 to 
CCR2 induces Ly6Chi monocytes to emigrate from the bone marrow, where they exist as a 
reserve population. Once in the circulation, Ly6Chi monocytes migrate to sites of inflammation, 









Section 1.5b: Macrophages 
 Macrophages are evolutionarily conserved phagocytes that are distributed throughout 
the tissues in the body. Macrophages can arise from, or independently of, circulating monocytes 
in the blood.(188) Macrophage populations that arise during embryonic development are able to 
persist into adulthood without contributions from circulating monocytes.(189–195) Tissue 
resident macrophages can be extremely heterogeneous. Macrophages can first be detected in 
the extraembryonic yolk sac during primitive erythropoiesis.(196) 
 
Section 1.5c: Macrophages in the Spleen 
Splenic RPMs are required for clearing senescent red blood cells (RBCs) and play an 
instrumental role in iron recycling. RPMs utilize the Spi-C transcription factor to drive the genes 
necessary for iron uptake (197, 198) and their development is dependent on the presence of 
Spi-C, with RPMs being depleted in Spic-/- mice.(197) During situations of increased hemolysis, 
increased heme can induce RPM cell loss and their subsequent replacement by circulating 
monocytes. Circulating monocytes then enter the spleen and upregulate Spi-C, leading to 
macrophage differentiation, reestablishment of the splenic RPM compartment, and restoration 
of iron homeostasis. These data provide further evidence that local signaling within tissues 
might be sufficient to promote the acquisition of specialized macrophage functions irrespective 
of the ontological lineage.(198)  
Macrophages are very heterogeneous and can be influenced by their microenvironment. 
For example, tissue resident macrophages, such as RPMs, can be distinguished by their gene 
expression patterns.(199) Furthermore, combinations of tissue- and lineage-specific 
transcription factors can form regulatory networks that control chromatin specification in tissue 
resident macrophages.(199) 
Other splenic macrophage populations are the marginal-zone macrophages (MZM) and 
marginal metallophilic macrophages (MMM). The development of MZMs and MMMs depend on 
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the nuclear receptor LXR, and they function to limit blood-borne infections.(200, 201) The outer 
layer of the marginal zone in the spleen, which is composed predominantly of B cells, contains 
MZMs. These MZMs express scavenger receptors and pattern recognition receptors.(200, 202) 
This, combined with their location, make them efficient at capturing blood-borne antigens.(63, 
200) Additionally, MZMs help regulate the retention of marginal zone B cells, which are needed 
to establish the architecture of the splenic marginal zone.(203, 204)  MMMs are found in the 
inner layer of the splenic marginal zone,(205) where they play a role in antiviral responses and 
responses to bacterial infections.(206, 207) Overall, MZMs and MMMs play important roles in 
immune surveillance. The white pulp of the spleen also contains macrophages, which can clear 
apoptotic cells during germinal center reactions.(208)   
 
Section 1.5d: Macrophage polarization 
 Macrophages respond to various stimuli. Their plasticity and adaptability make them an 
integral part of the immune system. Upon responding to various stimuli, macrophages can 
become activated or “polarized.” Previously, macrophage polarization was commonly 
categorized by classical or alternative activation, or M1 and M2, respectively. M1 stimuli are 
grouped based on their ability to stimulate an inflammatory response in macrophages. IFN-γ is 
the main cytokine associated with M1 polarization, as well as being a main Th1 product. IFN-γ 
in combination with LPS can induce the M1 state as well, with gene expression profiles of the 
combination being different from LPS or IFN-γ profiles alone.(209, 210) Pattern recognition 
receptors that are induced by pathogens are also examples of M1 polarization. Pathogens can 
activate macrophages through toll-like receptor (TLR) ligands, such as LPS, muramyl dipeptide, 
and lipoteichoic acid.(209) Granulocyte macrophage colony-stimulating factor (GM-CSF), TNF-
alpha, IL-1ß, and IL-6 are also M1 stimuli.  
 M2 polarization is characterized as being anti-inflammatory. IL-4 is one of the stimuli for 
this type of polarization state and is produced by the Th2 cells, eosinophils, basophils, and 
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macrophages themselves, and is recognized by multiple receptors. Combined immune 
complexes that contain TLR and/or IL-1 receptor agonists can induce an M2 polarization state, 
although it is distinct in expression from that induced by IL-4.(211, 212) Glucocorticoids and IL-
10 are also included in the M2 category, despite being very different types of stimuli.  
Glucocorticoid hormones are secreted by the adrenal glands and can be metabolized by 
cellular enzymes in macrophages. When glucocorticoid hormones bind the glucocorticoid 
receptor, it undergoes translocation to the nucleus. In the nucleus, the receptor binds to a 
glucocorticoid receptor-responsive element as a partner transcription factor, regulating gene 
expression either positively or negatively.(213) Cellular responses to glucocorticoids result from 
an interplay between at least three factors: the intracellular concentration of free hormone, the 
relative affinity of the particular glucocorticoid to its receptor, and the ability of the specific cell to 
receive and transduce the hormonal signal [3]. Active glucocorticoids, such as cortisol and 
corticosterone, can be converted into inactive 11-ketosteroids.(214) Active glucocorticoids are 
lipophilic and diffuse through the membrane to bind the glucocorticoid receptor. The 
glucocorticoid and glucocorticoid receptor complex binds DNA directly to promote or suppress 
gene transcription; alternatively, it acts indirectly by interacting with transcription factors, such as 
NF-κB or AP-1. IL-10 is secreted by DCs, B cells, cytotoxic T-cells, T-cells, NK cells, mast cells, 
neutrophils, eosinophils, monocytes, and macrophages.(215) IL-10 acts through a 
transmembrane receptor complex composed of IL-10R1 and IL-10R2. During this process, IL-
10/IL-10R1 interaction changes the cytokine conformation, leading to its dimerization with IL-
10R2, which ultimately activates Jak1/STAT3 signaling pathways.(215, 216) Macrophage 
colony stimulating factor (M-CSF) is also categorized as an M2 stimulus. Binding of M-CSF 
leads to receptor dimerization, autophosphorylation, activation of ERK, phosphatidylinositol 3-
kinase, and phospholipase C, and eventual Sp1 transcription factor nuclear localization, leading 
to activation of cell cycle genes.(210) 
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Variations on the M2 polarization state prompted an update to the nomenclature to 
include different subsets of M2 polarization based on the corresponding stimuli. Thus, M2a is 
induced by IL-4 or IL-13, M2b is induced by exposure to immune complexes and agonists of 
TLRs or IL-1R, and M2c is induced by IL-10 and glucocorticoid hormones.(217) As more 
information was obtained and techniques for studying macrophage activation expanded, 
additional activation states were added to the ever-growing list, including those found in 
atherosclerosis.  
Mox macrophages were identified in the context of atherosclerosis. Lipid accumulation 
and oxidative tissue damage are hallmarks of atherosclerotic lesions.(218) Macrophages are 
able to sense various lipid classes and respond to them accordingly with highly specific 
transcriptional programs and phenotypic changes.(219) Oxidized phospholipids are lipid 
oxidation products that accumulate during atherosclerosis and are present in atherosclerotic 
lesions. In macrophages, oxidized phospholipids induce a distinct transcriptional program that is 
driven by the redox-dependent transcription factor Nrf2.(220) This leads to upregulation of 
genes responsible for regulating redox, including heme oxygenase-1, glutathione reductase, 
glutathione synthase, thioredoxin reductase, and sulfiredoxin.(218) Upregulating these genes, 
as well as certain inflammatory genes, such as COX2 and IL1β, leads to the Mox polarization 
state.  
The platelet-derived chemokine, CXCL4, is abundant in atherosclerotic lesions (221, 
222) and induces a transcriptional profile in macrophages that is very different from those in M1 
or M2 macrophages, though some increases in the expression of some genes were shared. 
Genes upregulated in macrophages stimulated by CXCR4 include those involved the 
inflammatory/immune response, antigen processing and presentation, lipid metabolism, and 
cholesterol efflux transporters, with decreases in genes for scavenger receptors, which could 
result in lower low-density lipoprotein content.(223) Therefore, macrophages stimulated in this 
manner were characterized as M4 macrophages.(223) 
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 Intraplaque hemorrhage in atherosclerosis is a serious event that may significantly 
contribute to lesion destabilization. Therefore, it is plausible that repair mechanisms involving 
macrophages come into play. Macrophages responding to heme and hemoglobin in areas of 
plaque hemorrhage have been found to exhibit a distinct phenotype, referred to as Mhem.(224) 
Mhem macrophages are anti-inflammatory and are involved in tissue regeneration. They exhibit 
increased expression of HO-1, as well as LXRβ and LXRα, which are responsible for handling 
iron and lipids, respectively. This increase in expression was found to be induced by the ATF-1 




Section 1.6: RBC Storage 
Section 1.6a: The RBC storage lesion 
 RBC transfusions are a common therapeutic, with approximately 11 million units being 
transfused annually in the Unites States.(224) As part of the process for preparing RBCs for 
transfusion, whole blood is collected from donors and leukoreduced, if prepared in the United 
States and certain countries, immediately after collection. Blood is collected into 
anticoagulant/storage solutions that typically contain citrate, dextrose, and phosphate (e.g., 
CPDA-1) and then suspended into a storage solution (e.g., AS-3) to help maintain the viability 
and function of the RBCs until they are transfused into patients. The RBCs are packed by 
removing a portion of the plasma following centrifugation, thus increasing the ratio of RBCs to 
plasma in the total volume. Depending on the institution where the RBC units are prepared, the 
RBCs are also irradiated to destroy viable T cells, which may otherwise cause graft versus host 
disease (GVHD).   
 After this preparation, RBCs are stored at 4 ± 2 °C for up to 42 days. This criterion for 
maximum storage duration was set, somewhat arbitrarily, by the United States Food & Drug 
Administration (FDA). The goal of this storage duration is to have no less than 75% of the 
transfused RBCs maintained in the circulation in vivo at 24 hours following transfusion and less 
than 1% hemolysis present in vitro in the storage bag itself. 
 As the RBCs are stored they undergo a series of changes to their structure, function, 
and metabolism, collectively referred to as the “storage lesion.”(225) Glucose is consumed by 
the RBCs, levels of 2,3-diphosphoglycerate (2,3-DPG)(226–228) and adenosine triphosphate 
(ATP) decrease (226, 227, 229), and potassium levels increase. 2,3-DPG is the major allosteric 
modifier of oxygen affinity by hemoglobin. 2,3-DPG binds to the central compartment of the 
hemoglobin tetramer, leading to a change in conformation and a shift from a high-oxygen-affinity 
state to a low-oxygen-affinity state. 
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Morphologically, RBCs change from deformable biconcave disks to reversibly deformed 
echinocytes, to irreversibly deformed spheroechinocytes; a change that is readily observed 
under the microscope. In addition, the RBC undergoes vesiculation accompanied by membrane 
loss (230–233), protein oxidation (234, 235), and lipid peroxidation (236), ultimately leading to 
decreased deformability (237–240). Microvesicles can form that are composed of phospholipids 
and transmembrane proteins, leading to the changes in shape that are observed as RBC are 
stored (i.e. echinocytes and spheroechinocytes). These changes ultimately lead to decreased 
deformability and increased osmotic fragility (241–243) Possible mechanisms underlying the 
changes in the membrane relate to increased oxidative stress. For example, oxidation of the 
spectrin-actin-protein 4.1 complex has been correlated with vesiculation.(235, 244) Additionally, 
lipid peroxidation has been associated with decreased RBC deformability (245). As a result, the 
changes in the characteristics of the RBCs as part of the storage lesion can be harmful to them 





Figure 1.7: Storage lesion 
Summary of the RBC storage lesion. As the RBCs are stored they undergo a series of 
changes to their structure, function, and metabolism. During this process, erythrocytes 












Section 1.6b: Effects of transfusing storage-damaged RBCs in animal models  
 In an effort to study the effects of transfusing storage-damaged RBCs in vivo, a mouse 
model of RBC storage-damage and transfusion was established.(246) Blood from mice was 
collected, leukoreduced, packed to a ~75% hematocrit, and stored at 4°C in CPDA-1 storage 
solution for up to 14 days. At various time points during storage, RBCs were transfused into 
wild-type recipient mice and RBC survival was determined by flow cytometric analysis of the 
transfused fluorescent RBCs. After 12-14 days of storage at 4°C, the RBCs exhibited a 24-hour 
survival that was similar to the FDA requirement (~75%), with most clearance occurring by 2 
hours post-transfusion. The shortened, ~14-day, storage duration of murine RBCs that is 
required for ~75% survival at 24 hours, relative to the 42-day storage duration for human RBCs, 
may make sense, given that the endogenous lifespan of murine RBCs is ~45 days, as opposed 
to ~120 days for human RBCs.  
Using this mouse model of refrigerator storage and RBC transfusion, several studies in 
mice were completed assessing the effects of transfusing storage-damaged or “old” RBCs in 
vivo. Mice transfused with old RBCs exhibited increased levels of circulating inflammatory 
cytokines, such as CCL2, IL-6, and IL-8.(129) The rapid clearance of the transfused, storage-
damaged RBCs also led to the production of non-transferrin-bound iron (NTBI). Of note, these 
inflammatory effects were not seen when supernatant, hemolysate, or RBC membranes (i.e. 
“ghosts”) were infused. In additional studies, transfusion of old RBCs led to impaired host 
defenses against select Gram-negative bacteria.(247) For example, mice were given a 
transfusion of old RBCs and infected, concurrently, with either S. typhimurium or E. coli. The 
resulting bacterial infection in the recipients was exacerbated by the transfusions of old RBCs. 
In another study, transfusions of old RBCs led to increased alloimmunization to a foreign blood 
group antigen expressed on the transfused RBCs.(248) 
Studies in dogs similarly found that transfusions of old RBCs led to increased adverse 
effects. For example, increased mortality was seen in a pneumonia model in which dogs 
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received a transfusion of old RBCs.(151, 249, 250) Finally, in a guinea pig model, transfusions 
of stored RBCs, but not of fresh RBCs, led to intravascular hemolysis, acute hypertension, 
vascular injury, and kidney dysfunction.(251) These authors concluded that these results were 
likely associated with a pathophysiology driven by hemoglobin.   
 
Section 1.6c: Clinical effects of transfusing humans with storage-damaged RBCs 
 The overall effect in humans of transfusing old, storage-damaged RBCs is debated, with 
various studies suggesting that adverse events occur and others not finding an increase in the 
incidence of adverse events. However, caution should be taken when interpreting the results of 
clinical studies, as careful analysis of the patient populations that are tested should be taken 
into consideration when attempting to determine if transfusions of old RBCs are detrimental.  
For example, one study examined the effects of RBC transfusions on the incidence of 
subsequent bacterial infections in patients undergoing coronary artery bypass graft (CABG) 
surgery.(252) In this study of 533 patients, RBC transfusions were independently associated 
with a higher incidence of post-CABG bacterial infections.(252) Another study focusing on 
trauma patients sought to determine if transfusions of old RBCs led to increased infections 
using a prospective cohort study.(253) Transfusions of older RBCs were associated with 
subsequent infection, including when using RBCs stored for more that 21 days. Multivariate 
analysis confirmed storage time was as an independent risk factor for major infections.(253) Yet 
another study focused on evaluating the temporal relationship between transfusion and 
pneumonia, including determining the influence of the length of the storage interval. In this study 
of 1,615 patients, transfusion of exclusively older RBCs increased the risk of pneumonia. In 
addition, a study using a prospective database of trauma patients found that the age of the 
RBCs transfused in the first 6 hours was an independent risk factor for post-injury multiple organ 
failure, with older RBCs resulting in a higher risk.(254) Furthermore, in a retrospective study of 
patients admitted to an intensive care unit, the age of the transfused RBCs correlated with 
	 37 
mortality.(255) In an observational study of patients undergoing cardiac surgery, transfusion of 
RBCs that had been stored for more than 2 weeks was associated with a significantly increased 
risk of postoperative complications, as well as reduced short-term and long-term patient 
survival.(256)  
In contrast, several subsequent prospective, randomized studies attempted to address 
whether transfusing patients with older RBCs was more detrimental than with fresh RBCs. One 
important note, however, is that several of these studies did not address the effects of 
transfusions of RBCs that had been stored for as long as 35-42 days, the last week before 
outdate, when RBCs may be the most damaged. Therefore, these results should be interpreted 
with caution. For example, the Age of Red Blood Cells in Premature Infants (ARIPI) was a 
double-blind randomized controlled trial of 377 premature infants. This study concluded that a 
transfusion of fresher RBCs did not improve outcomes in premature, low-birth-weight infants. 
However, the median age of the “old” RBCs used involved only 14.6 days of storage.(257, 258) 
In addition, the Age of Blood Evaluation (ABLE) trial focused on the age of transfused RBCs in 
critically ill adults, comparing RBCs stored for less than eight days with “standard-issue” RBCs, 
which were stored for a mean of 22 days.(259) This study suggested that there was no benefit 
to transfusing fresh RBCs in this setting. The Informing Fresh vs. Old Red Cell Management 
(INFORM) trial also sought to determine if RBC storage had an effect on mortality after 
transfusion.(260) In this study, 31,497 patients were randomized. The median storage duration 
in the “old” transfusion storage group was 23.6 days, far shorter than the 42 days of storage that 
some RBC units undergo before being discarded. They observed no difference in the rate of 
death between the patients transfused with the freshest or oldest available RBCs. The Red Cell 
Storage Duration Study (RECESS) trial focused on the effects of RBC storage duration in 
patients undergoing cardiac surgery. They compared clinical outcomes after cardiac surgery in 
patients transfused with RBCs stored for ten days or less (“fresh”) or for 21 days or more (“old”), 
but did not find a difference in clinical outcome when patients received fresh versus old RBCs. 
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However, due to the substantial hemolysis that can occur during a cardiac bypass, these results 
may not necessarily be generalizable to other patient populations. As another example, the 
Tissue Oxygenation by Transfusion in severe anemia with Lactic Acidosis (TOTAL) trial 
examined the effect of transfusing RBCs with longer versus shorter storage duration on 
elevated blood lactate levels in children with severe anemia, typically having malaria and/or 
sickle cell disease.(261) The “fresh” RBCs were stored for less than 10 days, whereas the “old” 
RBCs were stored between 25-35 days. The results of this study did not find that transfusion 
with old RBCs led to worse outcomes in these patients. However, the maximal outdate in 
Uganda is 35 days and the patients in this study had substantial amounts of ongoing hemolysis 
at baseline from sickle cell disease and/or malaria. Finally, studies with healthy human 
volunteers found increasing hemolysis in vivo of transfused RBCs in proportion to increasing 
storage time before transfusion, with the most substantial effects occurring at 35-42 days of 
storage;(134) however, no adverse clinical effects were reported. 
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Section 1.7: Thesis Aims 
 Due to the frequency with which RBC transfusions are administered to patients, 
understanding the potential for adverse effects is extremely important. As described, RBC 
transfusions are associated with adverse effects, including an increased risk for bacterial 
infection.(253–255, 262–266) As part of the procedure for preparing RBCs for transfusion, 
donated RBCs are refrigerator-stored for up to 42 days, as established by FDA criteria. During 
the storage process, RBCs undergo multiple alterations (both structural and metabolic), 
collectively known as the “storage lesion.” (225) As a result, some storage-damaged RBCs are 
rapidly cleared from the circulation following transfusion, a process mediated predominantly by 
phagocytic cells in the liver and spleen (i.e., “extravascular hemolysis”).(129) Pathologic 
erythrophagocytosis has been associated with exacerbations of certain bacterial infections in 
mouse models, including those caused by E. coli (247, 267), S. aureus,(267) and S. 
typhimurium.(247, 267) Furthermore, patients with hemolytic disorders (e.g., sickle cell anemia) 
are more susceptible to certain infections.(268) 
 
Therefore, this project has two overarching aims:  
1. What is the overall effect of robust phagocytosis of storage-damaged (“old”) 
RBCs on the mononuclear phagocyte system? 
2. Does robust erythrophagocytosis by mononuclear phagocytes impair subsequent 




CHAPTER 2: Materials and Methods 
Section 2.1: Mice 
Mouse strains  
Wild-type C57BL/6, CCR2-/- (on a B6.129S4 background), and C57BL/6-Tg(UBC-GFP) 
mice were purchased from Charles River (Wilmington, MA, USA) or The Jackson Laboratory 
(Bar Harbor, ME, USA) (Table 2.1). MaFIA (Csfr1-EGFP) mice (on a C57BL/6 background) 
were a generous gift from Dr. Anthony Ferrante (Columbia University Medical Center, New 
York, NY, USA) (Table 2.1). Spic-/- mice (on a 129/SvEv background) were a generous gift from 
Dr. Kenneth Murphy (Washington University in St. Louis School of Medicine, St. Louis, MO, 
USA) (Table 2.1). CCL2-GFP reporter mice (on a C57BL/6 background) were a generous gift 
from Dr. Eric Pamer (Memorial Sloan Kettering Cancer Center; New York, NY, USA) (Table 
2.1). Mice were used at 6-12 weeks of age. All procedures were approved by the Institutional 
Animal Care and Use Committee at Columbia University. 
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Mouse Genotype Stock 
Number 







C57BL/6NCrl 027 Charles River No 
CCR2- B6.129S4-Ccr2tm1Ifc/J 004999 The Jackson Laboratory Yes, Black 
Building ICM 
Spi-C-/- 129S-Spictm1Kmm/J N/A Kenneth Murphy 
(Washington University 
School of Medicine in St. 






129sv N/A Kenneth Murphy 
(Washington University 
School of Medicine in St. 








N/A Eric Pamer (Memorial 





















Table 2.1: List of mouse strains used 
The mouse strains are listed with the source, either purchased from Jackson 
Laboratories or Charles River, or they were a generous gift from Drs. Ferrante, Murphy, or 
Pamer. For Spi-C-/- mice, heterozygotes were bred to generate the wild type and homozygous 
mutant mice that were used for the experiments, using the PCR genotyping protocol that is 
referenced later in this Methods section.  
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Genotyping Spic KO mice (129S-Spictm1Kmm/J) 
Tail biopsies or ear snips were taken from offspring of heterozygous breeding pairs. The 
tissue samples were added to a digestion buffer (10 mM Tris-HCl pH 8, 50 mM KCl, 0.5% NP-
40, 0.5% Tween-20) and boiled. Additional digestion buffer with Proteinase K was added to the 
samples and they were incubated at 52°C overnight. After the incubation, the samples were 
boiled to inactivate the Proteinase K and 2 μl of the digested samples were used for PCR 
reaction. The following primers were used for the PCR reaction: 
12016: GGC AAA CCT TCT CAG GGC AAG CAA GCA TCC 
12017: TAA CTG TGA TAA ACT ACC GCA TT 
12018: CTG AGA ACC TTC CAG GCA GTG TTT ACA TAT  
See Table 2.2 for PCR reaction and cycling instructions. The expected bands are as follows: 














ddH2O up to final volume 
		
Kapa 2G HS 
buffer 1.3 X 
MgCl2 2.6 mM 
dNTP KAPA 0.26 mM 
12016 0.5 uM 
12017 0.5 uM 
12018 0.5 uM 
Glycerol 6.5 % 
Dye 1 X 
Kapa 2G HS taq 
polymerase 0.03 U/ul 
DNA 50-200 ng 
 
 
Cycling   
 Step # Temp °C Time Note 
1 94 2 min 		
2 94 20sec 		
3 65 15sec -0.5 C per cycle decrease 
4 68 10sec 		
5 
		 		 repeat steps 2-4 for 
10 cycles 
(Touchdown) 
6 94 15sec 		
7 60 15sec 		
8 72 10sec 		
9 		 		 repeat steps 6-8 for 28 cycles 
10 72 2 min 		
11 10 		 hold 
 
Table 2.2: Spic-/- PCR genotyping protocol 
Reaction components and PCR cycling protocol for genotyping 129S-Spictm1Kmm/J 
(Spic-/-) mice from The Jackson Laboratory.(269)  
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Section 2.2: RBC preparation and transfusions 
RBC collection  
Wild-type C57BL/6 mice or UBC-GFP mice were bled aseptically via cardiac puncture 
and pooled whole blood was placed in CPDA-1 solution that was obtained from di-(2-
ethylhexyl)phthalate-plasticized polyvinyl chloride human primary collection packs (4R3611 
Baxter; Deerfield, IL, USA) to a final concentration of 15% CPDA-1. Whole blood was then 
leukoreduced using a Neonatal High-efficiency Leukocyte Reduction Filter (Purecell Neo; 
Haemonetics; Braintree, MA, USA). Leukoreduced blood was centrifuged at 1000 x g for 10 
minutes to pack the RBCs and a portion of the plasma-containing CPDA-1 supernatant was 
removed to yield a ~75% hematocrit. Leukoreduced, packed RBCs were either used “fresh” 
(i.e., stored for less than 24 hours at 4°C) or “old” (i.e., stored for 12-14 days at 4°C). 
 
RBC transfusions 
  Isoflurane-anesthetized mice were transfused with either 200 or 350 µl of packed RBCs 
through the retro-orbital plexus. At defined times post-transfusion, mice were anesthetized with 
isoflurane, sacrificed, and the spleen, bone marrow, and blood were collected. 
 
Antibody-coating RBCs  
Anti-RBC antibody (rabbit polyclonal, Rockland Immunochemicals Inc; Limerick, PA, 
USA) was added to Phosphate-buffered saline (PBS) at a dilution of 1:500. The volume of PBS 
used was determined based on the volume of RBCs being labeled, with 2.5 ml of PBS used for 
every 100 μl RBCs. Collected RBCs were then added to the diluted anti-RBC antibody and 
gently inverted several times to mix. The RBC/antibody mixture was then incubated at 37°C for 
1 hour, with intermittent mixing by inverting the tube. Following incubation, RBC/antibody 
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mixture was centrifuged to pellet the cells and the supernatant was removed. The IgG-coated 
RBCs (IgG-RBCs) were then washed 2 times with PBS.  
 
Heat-damaged RBCs 
RBCs were incubated at 50°C for 20 minutes. After incubation, RBCs were placed on ice 
to stop the heating.  
 
Fluorescent labeling of RBCs  
Carboxyfluorescein succinimidyl ester (CFSE; eBioscience; San Diego, CA, USA) was 
re-suspended in Dimethyl sulfoxide (DMSO; Invitrogen, Carlsbad, CA, USA) to create a stock 
solution with the concentration of 50 μg/μl. CSFE stock solution was added to PBS to create a 
1.5 mg/ml CSFE working solution for infusion into mice. 200 μl of the CSFE working solution 
(300 μg/mouse) was infused into recipient wild-type C57BL/6 mice through retro-orbital 
injection. Blood was then collected, as described above, to prepare leukoreduced blood banks 
24 hours post-infusion to ensure that no unbound dye remained in the circulation and that any 
damaged RBCs would be removed from the circulation by the donor’s immune system.  
 
Section 2.3: Surface and intracellular staining 
Microscopy, immunofluorescence staining  
Frozen sections were thawed and allowed to air dry for 10-20 minutes. Using a PAP 
pen, a boundary was drawn around each section to minimize the volume of reagents needed to 
stain the tissue sections. The sections were fixed in 4% paraformaldehyde (Electron Microscopy 
Sciences; Hatfield, PA, USA) for 10 minutes and then washed 3 times, for 2 minutes each. 
Blocking buffer (1% BSA, 0.2% Triton-X, 5% goat serum in PBS, Sigma; St. Louis, MO, USA) 
was added and the slides were incubated for 1 hour at room temperature. After incubation, 
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blocking buffer was removed and primary antibody, diluted in blocking buffer, was added and 
the slides were left to incubate at room temperature for 1 hour at room temperature. The slides 
were then washed 3 times with PBS and then incubated with secondary antibody for 30 minutes 
– 1 hour at room temperature. The antibodies used are included in Table 2.3. The slides were 
then washed and 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI; Invitrogen) was added 
and left to incubate for 10 minutes. The slides were washed again and mounted using 
Fluoromount-G (SouthernBiotech; Birmingham, AL, USA) and imaged using the Leica DMI 




Antibody Clone Manufacturer Location Catalog Number 
F4/80 BM8 eBioscience San Diego, 
CA, USA 
14-4801-82 
SIGN-R1 eBio22D1 eBioscience San Diego, 
CA, USA 
14-2093-81 
CD169 3D6.112 Invitrogen Carlsbad, CA MA5-16508 
 
Secondary Antibodies 
Antibody Fluorophore Manufacturer Location Catalog Number 
Goat pAb to ArHm Alexa Fluor 647 Abcam Cambridge, 
UK 
ab173004 
Goat anti-rat IgG 
(H+L) 
Alexa Fluor 647 Life Technologies Carlsbad, CA A21247 
Goat anti-rat IgG 
(H+L) 
Alexa Fluor 555 Life Technologies Carlsbad, CA A21434 
 
Table 2.3: Antibodies used for immunofluorescence microscopy 
Antibodies used for immunofluorescence microscopy with clone, company, location of 




Cell isolation, flow cytometric analysis, and sorting 
Splenocytes were isolated after homogenizing spleens using a round bottom tube with 
cell strainer snap cap (Becton Dickinson (BD) Falcon; Franklin Lakes, NJ, USA). Bone marrow 
was harvested by flushing the femur with a 25G 5/8” needle (BD) using PBS containing 1% fetal 
bovine serum (FBS; HyClone, GE Healthcare; Chicago, IL, USA). Following RBC lysis, 1 x 106 
cells were blocked using rat anti-mouse CD16/CD32 (BD Pharmingen; San Jose, CA, USA) in 
PBS containing 1% FBS. Cells were then stained with conjugated antibodies to various surface 
markers (Table 2.4) in 1% FBS/PBS buffer by incubating the cells at 4°C for 35-45 minutes. 
Following the incubation, the cells were washed with 1% FBS/PBS buffer and resuspended to a 
concentration of 106 cells/300 μl in 1% FBS/PBS containing a 1:1000 dilution of DAPI to 
determine viability of the cells during analysis. Cell suspensions were analyzed using the LSRII, 
LSRFortessa, or C6 Accuri cytometers (BD). Cell sorting was performed using the Influx 
instrument (BD). All flow cytometry data were analyzed with FlowJo software (BD; Ashland, OR, 
USA) or FCS Express software (De Novo Software; Los Angeles, CA, USA). The gating 
strategy for selecting live cells is included in Figure 2.1. 
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Antigen Clone Manufacturer 
CD11b   M1/70 eBioscience 
CD11c N418 Biolegend 
F4/80 BM8 Biolegend 
Ly6C HK1.4 Biolegend 
Ly6G 1A8 Biolegend 
TCR-ß H57-597 Biolegend 
CD19 6D5 Biolegend 
CD3e 145-2C11 eBioscience 
B220 RA3-6B2 Biolegend 
CD45 30-F11 Biolegend 
MHCII M5/114.152 Biolegend 
CD115 AFS98 Biolegend 
VCAM-1 429 Biolegend 
CD86 GL-1 Biolegend 
CD206 C068C2 Biolegend 
CD71 C2 BD Biosciences 
CD169 3D6.112 Biolegend 
Ter-119 Ter-119 Biolegend 
 
 
Table 2.4: Antibodies used for staining surface antigens 
Antibodies used for flow cytometry and FACS. Descriptive information includes targeted 







Figure 2.1: Gating strategy for selecting live, single cells by flow cytometric analysis 
The first gate (left panel) select for cells, leaving out dead cell debris. The next gate was 
drawn to select for single cells (FSC-A vs FSC-H; middle panel) followed by selecting for DAPI- 












Annexin V Staining  
10X Annexin V Binding Buffer (BD Biosciences) was diluted to 1X using distilled water. 
Cells were stained for select surface antigens and then washed in serum-free PBS. Cells were 
resuspended in 1 ml of 1X Annexin V Binding Buffer to create a 1x106/ml cell suspension. 100 
µl of this cell suspension was used to provide 1x105 cells, and 5 µl of Annexin V (FITC, BD 
Pharmigen) was added to each sample. Samples were then incubated 15 minutes at room 
temperature in the dark. Following incubation, 400 µl 1X Annexin V Binding Buffer was added to 
each sample and cells were analyze using flow cytometry. 
 
Intracellular staining for Ki67 
Cells were first stained with eBioscience Fixable Viability Dye. Cells were then washed 
and fixed by adding 100 µl Fixation Buffer (eBioscience) while vortexing. Cells were then 
incubated for 20 minutes at room temperature in the dark. Without washing, 2 ml of 1X 
Permeabilization Buffer (eBioscience) was added to each sample, followed by centrifugation for 
5 minutes 300-400 x g. Cells were resuspended in 100 µl of 1X Permeabilization Buffer (1 x 106 
cells/100 µl) and 20 µl of anti-Ki-67 antibody (clone B56) were added. The samples were mixed 
gently and incubated at room temperature for 20-30 minutes in the dark, followed by washing 
the cells with 2 ml 1% FBS/PBS at 200 x g for 5 minutes. The cells were then resuspended in 
300 µl and analyzed by flow cytometry.  
 
Lipid peroxidation and ROS studies 
To measure lipid peroxidation, splenocytes, J774A.1 cells (J774; purchased from ATCC; 
Manassas, VA, USA), or bone marrow-derived macrophages (BMDMs; see below) were 
incubated with C11-Bodipy 581/591 (Molecular Probes, Invitrogen) following either transfusion 
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in vivo or incubation with RBCs in vitro at 37°C. Isolated cells were washed twice with PBS 
containing 1% FBS and then either stained for surface markers or immediately analyzed by flow 
cytometry, where increases in lipid peroxidation were determined by increases in intensity in the 
FL-1 channel. To measure ROS production, splenocytes, J774 cells, or BMDMs were incubated 
with 2',7'-dichlorodihydrofluorescein diacetate (H2-DCFDA; Molecular Probes, Invitrogen) for 30 
minutes at 37°C following transfusion or incubation with RBCs. Cells were washed twice and 
then either stained for surface markers or immediately analyzed by flow cytometry. 
 
Section 2.4: Gene expression analysis 
Quantitative reverse-transcriptase PCR 
Designated splenic macrophage and monocyte populations were sorted into TRIzol 
(Invitrogen) for RNA extraction followed by processing with SuperScript VILO (Invitrogen) for 
cDNA synthesis. Quantitative PCR was then performed using QIAGEN (Germantown, MD, 
USA) RT2 SYBR Green master mix and normalized to the housekeeping gene GAPDH. The 
primers (Integrated DNA Technologies; Coralville, IA, USA) used are listed in Table 2.5. 
The cDNA samples were run on the AriaMx Real Time PCR System (Agilent 
Technologies; Santa Clara, CA) with the following protocol: 1 cycle at 95°C for 10 minutes, 40 
cycles at 95°C for 15 seconds then 60°C for 1 minute, and 1 cycle at 95°C for 30 seconds, 95°C 
for 30 seconds, and 95°C for 30 seconds. The data was analyzed using The GeneGlobe Data 
Analysis Center, which is a web resource for analyzing real-time PCR data. The real-time PCR 
modules transform threshold cycle (CT) values to calculated results for gene expression and 




Table 2.5: Real time PCR primers 
Gene Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) 
GAPDH ATGACTCCACTCACGGCAAATTC ACACCAGTAGACTCCACGACATAC 
CCL7 GGTGTCCCTGGGAAGCTGTTAT TATAGCCTCCTCGACCCACTTCT 
CCL2 CCTGGATCGGAACCAAATGAGATCAG AGTGCTTGAGGTGGTTGTGGAA 
Hmox1 TCA AGC ACA GGG TGA CAG AAG AG GTG AGG GAC TCT GGT CTT TGT GTT 
CD163 ACGGTGTGTGACGACAACTTCA GGTCCAGAACCAGCTCCCAATTTA 
IL-1 CTG GTG TGT GAC GTT CCC ATT AGA TCC ATT GAG GTG GAG AGC TTT CAG 
IL-10 CTG CTA TGC TGC CTG CTC TTA CT ACT GGG AAG TGG GTG CAG TTA TT 
Arg-1 ACA GGG CTC CTT TCA GGA CTA GAT A GTT CCG AAG CAA GCC AAG GTT AAA G 
MMR CCG TGG TCC TCC TGA TTG TGA TAG AAA GGT GGC CTC TTG AGG TAT GT 
IL-12 GCT CAT GGC TGG TGC AAA GAA A AGA CAG AGA CGC CAT TCC ACA T 
TNF-
alpha 
TGG CCT CCC TCT CAT CAG TTC TA TCC ACT TGG TGG TTT GCT ACG A 




RNA was amplified using SMART-seq v4 Ultra Low Input RNA Kit (Clontech, Mountain 
View, CA) to create amplified cDNA, followed by library preparation using the Nextera XT kit 
(Illumina, San Diego, CA). Libraries were sequenced in multiplex targeting 30 million single-end 
100 bp reads per sample on an Illumina HiSeq2000 at the Columbia University Genome Center. 
BCL and bcl2fastq programs were used to convert BCL to FASTQ format, coupled with adaptor 
trimming. Reads were mapped to a reference genome (UCSC/mm9) using TopHat with 4 
mismatches and 10 maximum multiple hits. Binary alignment map (BAM) files were generated 
by TopHat to map reads to annotated genes, and converted to an annotated count matrix, using 
the Rsamtools and GenomicAlignments R packages. Data were then analyzed using DESeq to 
obtain differential expression analysis and principal component analysis. Pathway analysis was 
performed using PANTHER, with pathway data from the GO gene ontology database. 
 
Section 2.5: Adoptive transfer 
Bone marrow was collected from the femurs, tibia, and pelvis of UBC-GFP mice by 
crushing the bones with a pestle, followed by filtering with a 70 μm Nylon mesh (FisherBrand; 
Pittsburgh, PA, USA) while flushing with chilled 1% FBS/PBS buffer. Cells were then pelleted at 
400 x g and RBCs were lysed. The cells were incubated with rat anti-mouse CD16/CD32 (BD 
Pharmingen) and then with biotinylated antibodies recognizing the following antigens for 
negative selection of monocytes: CD11c (N418), CD3e (145-2C11; eBioscience), Ly6G (1A8), 
B220 (RA3-6B2), F4/80 (BM8, eBioscience), NK1.1 (PK136), CD49b (DX5), and CD34 (RAM34, 
eBioscience); all antibodies were purchased from Biolegend (San Diego, CA, USA), unless 
otherwise indicated. Following incubation with surface markers, the cells were washed with 1% 
FBS/PBS buffer, followed by centrifugation at 400 x g for 5 minutes. The sample was mixed and 
incubated with Anti-Biotin MicroBeads (Miltenyi Biotec; Bergisch Gladbach, Germany) for 10 
	 55 
minutes at 4°C. Following incubation, the cells and bound magnetic beads were applied to 
magnetic columns. The flow through was collected, containing the monocytes isolated by 
negative selection. Monocytes (1 x 106) were infused into anesthetized mice through the retro-
orbital plexus followed by infusions of PBS or transfusions of old RBCs. 
  
Section 2.6: Cell Culture Assays 
In vitro erythrophagocytosis assay 
J774 cells were cultured in Dulbecco’s minimal essential medium (DMEM) 
supplemented with 10% FBS, 2 mM L-glutamine, penicillin (50 units/ml), and streptomycin (50 
µg/ml). To prepare primary BMDMs, mononuclear cells obtained from mouse femurs were 
cultured in 20 ng/ml M-CSF (PeproTech; Rocky Hill, NJ, USA) in Iscove’s Modified Dulbecco’s 
Medium (IMDM) supplemented with 10% FBS, 2 mM L-glutamine, penicillin (50 units/ml), 
streptomycin (50 µg/ml), and 20 µg/ml gentamycin (Gibco, Life Technologies) for 7-11 days. 
J774 cells or BMDMs were plated 24 hours prior to the day of the experiment. On the day of the 
experiment, fresh RBCs were fluorescently labeled with CellTrace Far Red (Invitrogen) and then 
incubated with IgG anti-RBC antibody at 0.5 mg/ml (rabbit anti-mouse, polyclonal, Rockland 
Immunochemicals) to generate opsonized, IgG-RBCs. Adherent phagocytes were then 
incubated with PBS, non-opsonized RBCs, or IgG- RBCs for 2 hours at 37°C. Following 
incubation, non-ingested RBCs were lysed and adherent cells were removed by scraping or by 
incubation with Accutase (eBioscience) at 37°C. Cells were then analyzed by flow cytometry.  
 
High-throughput microscopy assay 
Cells harvested from the bone marrow were cultured in the presence of 20 µg/ml M-CSF 
for 7 days to generate BMDMs. 10,000 – 12,000 BMDMs were then plated per well in black 
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polystyrene 96-well plates (Greiner; Monroe, NC, USA) 72 hours prior to the experiment. On the 
day of the experiment, adherent cells were incubated with PBS, non-opsonized RBCs, or IgG-
opsonized RBCs in combination with defined concentrations of ferrostatin-1 (Fer-1; Sigma) or 
DMSO (vehicle control; Invitrogen) for 6 hours. Non-ingested RBCs were lysed and adherent 
cells stained with DAPI (Invitrogen) to determine cell viability and total cell number, respectively. 
Plates were imaged on the IN Cell Analyzer 2000 (GE Healthcare) and analyzed using IN Cell 
Investigator Software (GE Healthcare).  
 
In vitro erythrophagocytosis and infection assays 
J774 (ATCC) were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 
penicillin (50 units/ml), and streptomycin (50 µg/ml). To prepare primary BMDMs, mononuclear 
cells from mouse femurs were cultured in 20 ng/ml macrophage-colony stimulating factor (M-
CSF; PeproTech) in IMDM, supplemented with 10% FBS, 2 mM L-glutamine, penicillin (50 
units/ml), streptomycin (50 µg/ml), and 20 µg/ml gentamycin (Gibco, Life Technologies) for 7-11 
days. J774 cells or BMDMs were plated 24 hours prior to the day of the experiment. On the day 
of the experiment, fresh RBCs were fluorescently labeled in vitro with CellTrace Far Red 
(Invitrogen; Carlsbad, CA, USA) and then incubated with IgG anti-RBC antibody at 0.5 mg/ml 
(rabbit anti-mouse, polyclonal, Rockland Immunochemicals) to generate opsonized RBCs. 
Adherent phagocytes were incubated with PBS, non-opsonized RBCs, or opsonized RBCs for 2 
hours at 37°C. Following incubation, non-ingested RBCs were lysed, the monolayers were 
washed, and then incubated with fluorescently-labeled IgG-RBCs, S. aureus (200:1 ratio of 
bacteria:RBCs), or E. coli (200:1 ratio of bacteria:RBCs) for 30 minutes at 37°C. Following this 
second incubation, non-ingested RBCs were lysed, adherent cells were removed by scraping, 




Section 2.7: Bacterial infections 
Bacteria  
Bioluminescent S. aureus, strain Xen 36 (ATCC) and bioluminescent enteropathogenic 
E. coli, Strain Xen 14 (PerkinElmer, Waltham, MA), were used. For each experiment, a sample 
from a frozen stock of bacteria was inoculated into Lysogeny Broth (BD). In some experiments, 
bacteria were then washed twice in PBS and re-suspended to the appropriate number of colony 
forming units (CFUs)/µL in PBS by correlating absorbance at 600 nm to CFUs.  
 
Fluorescently labeling bacteria 
S. aureus, strain Xen 36, and E. coli, Strain Xen 14, were inoculated in LB 16 hours prior 
to labeling. The bacteria were washed with PBS twice by centrifuging bacteria for 8 min at 4,200 
× g, at room temperature, and discarding the supernatant. The pellet was then resuspended in 
FITC/PBS: 0.3 mg/ml FITC (fluorescein isothiocyanate) isomer 1 (Sigma) dissolved in PBS for a 
final concentration of 109 cells/ml. The bacteria were then incubated at room temperature for 1 
hour. After the incubation, the bacteria were washed with PBS three times by centrifuging 
bacteria for 8 min at 4200 × g, at room temperature, and discarding the supernatant. The 
bacteria were resuspended to a final concentration of 5 x 108/ml, based on the absorbance at 
600 nm to calculate CFUs.  
 
RBC transfusions and bacterial infections  
 Isoflurane-anesthetized mice were transfused with either 200 or 350 µl of packed RBCs 
through the retro-orbital plexus. At various time points after the transfusion, defined mouse 
cohorts were also infected intravenously with 1 × 108 CFUs of E. coli or S. aureus. At select 
times post-transfusion, mice were anesthetized with isoflurane, sacrificed, and the spleen was 
collected for flow cytometric analysis. 
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Section 2.8: Imaging luciferase activity in vivo 
At specified times following infection with E. coli Xen 14 or S. aureus Xen 36, 
bioluminescent imaging was performed in vivo using an imaging system (IVIS Spectrum, 
PerkinElmer). Mice were intraperitoneally injected with 10 µl/g of body weight of 15 mg/ml 
luciferin (PerkinElmer) stock solution. After allowing the luciferin to distribute in the mice for 10-
15 minutes, the mice were anesthetized with isoflurane and imaged. Bioluminescent flux, 
measured in photons per second emitted from specific regions, was quantified using computer 
software (Living Image, PerkinElmer); luciferase activity is expressed as photons per second. 
 
Section 2.9: Assessment of RBC recovery and clearance in vivo by flow cytometry 
Old, refrigerator storage-damaged fluorescent RBCs were transfused into recipient mice. 
Five minutes post-transfusion, tail pricks were taken to collect ~3 µl of blood to analyze by flow 
cytometry (C6 Accuri; BD) to determine the percentage of fluorescent cells in the blood. This 
value was used as a baseline to represent approximately 100% transfused RBC recovery (i.e. 
no RBC clearance). At 1 hour, 2 hours, and 24-hours post-transfusion, additional blood samples 
from recipients were taken by tail prick and analyzed. The percent remaining fluorescent RBCs 
was calculated as a ratio to the sample collected at 5 minutes post-transfusion to determine 
relative recovery.  
 
Section 2.10: Statistical Analysis 
Values on graphs are depicted as mean ± SD. Calculations for statistical differences 
between various groups were performed by the ANOVA technique and the Sidak, Tukey, or 
Dunnett post-test to correct for multiple comparisons, which are indicated in the figure legends. 
Otherwise, a two-tailed unpaired Student’s t test was used. Statistical significance is expressed 
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as follows: *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001. GraphPad (La Jolla, CA, USA) 
PRISM software version 6.0 was used for all statistical analyses. 
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CHAPTER 3: RBC clearance in the spleen 
Adapted and expanded significantly from: Youssef LA, Rebbaa A, Pampou S, Weisberg SP, 
Stockwell BR, Hod EA, Spitalnik SL. Increased erythrophagocytosis induces ferroptosis in red pulp 
macrophages in a mouse model of transfusion. Blood. 2018 Jun 7;131(23):2581-2593. 
  
 RBC transfusions are a common therapeutic, used in a wide range of settings (e.g., 
trauma). Therefore, potential outcomes, positive or negative, have special clinical relevance. 
Preparation of RBC units for transfusion involves refrigerated storage for an extended period of 
time, during which RBCs undergo multiple metabolic and physical changes, collectively known 
as the “storage lesion.” As a result, a proportion of the stored RBCs are rapidly cleared from the 
circulation post-transfusion by macrophages in the liver and spleen. Using a mouse model of 
storage-damaged RBC transfusion and clearance, wild-type C57BL/6 mice were transfused with 
fresh (i.e., <24 hours after collection) or 12-14-day stored RBCs, and splenocytes were 
analyzed at defined time points post-transfusion. By 2 hours post-transfusion, a significant 
portion of splenic red pulp macrophages (RPMs; VCAM-1+, F4/80hi, CD11blo) had ingested 
stored RBCs, but not fresh RBCs. Other phagocytes, such as Ly6C+ monocytes (Ly6Chi, 
CD11b+, CD115+, Ly6G-) and granulocytes (Ly6G+, Ly6Chi, CD11b+) cleared far fewer RBCs. 
Macrophages in the bone marrow also cleared old RBCs, indicating that this process occurs at 




Section 3.1: Introduction 
Erythrophagocytosis of senescent RBCs is important for the physiological iron recycling 
necessary for normal erythropoiesis. In humans, RBCs have a lifespan of ~120 days, before 
being recycled by hepatic and splenic phagocytes. However, multiple disorders lead to a 
shortened RBC lifespan and increased or pathologic erythrophagocytosis, including malaria 
(270), IgG-mediated hemolytic transfusion reactions (271), warm-type autoimmune hemolytic 
anemia (272), and acute hemolytic crises in sickle cell disease or glucose-6-phosphate 
dehydrogenase deficiency (273). RBC transfusions can also induce a rapid increase in 
erythrophagocytosis due to acute clearance of refrigerator storage-damaged RBCs (129). Given 
the critically important role that phagocytes play in host defense, if acutely increased 
erythrophagocytosis harmed phagocyte function, this could predispose the host to transfusion-
mediated immunomodulation (TRIM) and, possibly, harmful infectious consequences.  
In the United States of America, human donor RBCs are refrigerator-stored for up to 42 
days (according to guidelines of the FDA), during which time they undergo multiple structural 
and metabolic alterations, collectively known as “the storage lesion” (274–277). As a result, a 
substantial proportion of storage-damaged RBCs (i.e., up to 25%) can be rapidly cleared from 
the circulation after transfusion, primarily by hepatic and splenic phagocytes.   
In our mouse model, transfusions of refrigerator storage-damaged (i.e., “old”) RBCs 
enhanced erythrophagocytosis by splenic red pulp macrophages (RPMs). RPMs also cleared 
IgG-coated and heat-damaged RBCs, supporting their important role in iron recycling. We also 
found the splenic Ly6Chi monocytes contributed to clearance of old RBCs and IgG-coated 
RBCs, demonstrating that multiple cell types are involved in clearing damaged RBCs from the 
circulation in the spleen.  
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Section 3.2: Results  
RPMs are the predominant splenic population that clears old transfused RBCs  
To elucidate the various cell types involved in clearing transfused storage-damaged 
RBCs, we utilized an established mouse model of RBC storage and transfusion.(278) Using the 
FDA guidelines of requiring at least 75% of transfused RBCs to remain in the circulation 
following transfusion, this model demonstrated that packed RBCs that were stored in an 
appropriate storage solution for 12-14 days at 4°C exhibited approximately 75% RBC survival. 
Therefore, using this model of transfusion and storage damage, we collected blood from wild 
type C57BL/6 mice, the blood was leukoreduced, an appropriate amount of CPDA-1 storage 
solution was added, and the packed RBCs were stored at 4°C for 12-14 days. Following 
storage, mice were transfused with either 200 µl or 350 µl, corresponding to the human 
equivalent of roughly 1 unit and close to 2 units, respectively. Blood from UBC-GFP donor mice 
was used to be able to detect which cells had phagocytosed RBCs. Mice were then sacrificed 
and spleens were removed to analyze various cell populations for erythrophagocytosis by flow 
cytometry.  
By 2 hours after transfusing 200 µl of fresh or old packed RBCs into recipient mice, a 
significant proportion of splenic RPMs (VCAM-1+, F4/80hi, CD11blo) had already ingested old, 
but not fresh, RBCs (38.2% and 2.1%, respectively) (Fig. 3.1 and 3.2). This clearance of old 
transfused RBCs occurred rapidly, and erythrophagocytosis dramatically decreased by 24 hours 
post-transfusion (Fig. 3.2). The increase in erythrophagocytosis also coincided with an increase 
in Hmox1 mRNA content (Fig. 3.3); its protein translation product, heme oxgenase-1 (HO-1), is 
required to metabolize and detoxify heme. Splenic Ly6Chi monocytes (Ly6Chi, CD11b+, CD115+, 
Ly6G-) also cleared old RBCs, however, at a lower level than RPMs (7.02%, Fig. 3.1); they also 
exhibited increased Spic mRNA expression, a heme responsive gene (198), by 5 hours post-
transfusion (Fig. 3.4A). In contrast, splenic granulocytes, as well as those in the bone marrow 
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and the circulation, which are typically highly active phagocytes, particularly for pathogenic 
bacteria and IgG-coated RBCs (279), exhibited very little erythrophagocytosis in this setting 
(Fig. 3.1, 3.2, 3.7, 3.8). CD8+ and CD11b+ DCs also displayed low levels of erythrophagocytosis 
(3.70%, Fig. 3.1, 3.2), both at 2 and 24 hours post-transfusion. In contrast, splenic lymphocytes 
did not ingest old RBCs (Fig. 3.2). Taken together, these results highlight the major role that the 
mononuclear phagocyte system, particularly splenic RPMs, plays in clearing old transfused 
RBCs.  
Changes in surface levels of CD11b, CD86, and CD206 was observed in RPMs at 2 and 
5 hours post-transfusion, demonstrating an altered activation state (Fig 3.3A). Surface levels of 
these markers was observed to return to steady-state levels by 1 day post-transfusion, 
suggesting that the potential alteration in phenotype was short-term. Gene expression analysis 
revealed that RPMs decreased expression of CD163, IL-1, IL-10, Arg, and MMR (Fig 3.3B). 
Conversely, expression of IL-12, TNF-alpha, and Hmox1 increased by 5 hours post transfusion, 
further supporting the observation that RPMs were undergoing a change in the activation, and 
potentially, polarization state (Fig 3.3B).  
Ly6Chi monocytes demonstrated a dramatic increase in SpiC gene expression, which is 
important for iron metabolism, at 5 hours post-transfusion (Fig 3.4A). To elucidate the effect of 
erythrophagocytosis on this population of monocytes further, gene expression was analyzed in 
Ly6Chi monocytes from mice that received fresh RBCs, or from mice that received a transfusion 
of old RBCs and were then sorted by flow cytometry into a subpopulation that had ingested old 
RBCs and a subpopulation that had not. Principal component analysis of RNA sequencing data 
revealed that splenic Ly6Chi monocytes from these separate types of exposure clustered 
together (Fig 3.4B). As expected, genes involved in iron metabolism (e.g., Hmox1, Spic, 
Slc40a1, Fth1, and Ftl1) increased their expression in mice receiving an old RBC transfusion, 
with a further increase in the cells that had actually ingested RBCs (Fig 3.4C). Pathway analysis 
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using PANTHER(280) with a false discovery rate (FDR) cutoff of 0.5 showed that ingestion of 
old RBCs led to alterations in a broad set of pathways (Fig 3.4D). Notably, this list included 
those for regulating inflammatory responses and phagocytosis, as well as metabolic processes, 
suggesting that the cells were in an activated and inflammatory state after erythrophagocytosis. 
Further examination of the erythrophagocytosis capacity of RPMs revealed that they can 
also clear heat-damaged RBCs and IgG-coated RBCs (Fig 3.5). Splenic Ly6Chi monocytes also 
appeared to ingest IgG-coated RBCs, but not heat-damaged RBCs (Fig 3.5). Splenic 
granulocytes ingested IgG-coated RBCs, but not heat damaged RBCs, likely due to the Fc 
receptors on their surface, which are capable of mediating internalization of the RBCs coated 




Figure 3.1: RPMs are the predominant splenic population that ingests transfused old 
RBCs 
Wild-type C57BL/6 mice were transfused with 200 μl of PBS, fresh GFP+ RBCs, or old 
GFP+ RBCs. Mice were sacrificed at 2 or 24 hours post-transfusion, spleens were removed, 
single cell suspensions were prepared, and cells were analyzed by flow cytometry. 
Representative dot plots show the gating strategy for RPMs (F4/80hi, VCAM-1+, CD11blo), 
Ly6Chi monocytes (Ly6Chi, CD11bhi), granulocytes (Ly6G+, Ly6C+, CD11b+), CD8+ DCs (CD8+, 
CD11b-, MHCIIhi, CD11chi), and CD11b+ DCs (CD8-, CD11b+, MHCIIhi, CD11chi) at 2 hours post-
transfusion. Percentages of GFP+ cells are depicted; these represent nucleated cells that have 




Figure 3.2: Erythrophagocytosis in the spleen occurs shortly after transfusion of old 
RBCs   
Wild-type C57BL/6 mice were transfused with 200 μl of PBS, fresh GFP+ RBCs, or old 
GFP+ RBCs. Mice were then sacrificed at 2 or 24 hours post-transfusion. Frequency of GFP+ 
RBC phagocytosis at 2 and 24 hours post-transfusion, along with means for RPMs, Ly6Chi 
monocytes, and granulocytes; by 24 hours post-transfusion the levels of phagocytosis were 
dramatically reduced compared to the 2-hour time point and the previously ingested GFP+ 
RBCs were degraded. Data are representative of 4 experiments with at least 3 mice per group. 





3.3: Erythrophagocytosis alters gene expression in RPMs  
(A) Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old GFP+ RBCs. At various 
time points post-transfusion, RPMs were analyzed by flow cytometry to determine the levels of selected 
surface markers. (B) Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old GFP+ RBCs. At 
various time points post-transfusion, RPMs were collected by FACS for gene expression analysis. Fold 
regulation of CD163, TNF-alpha, IL-1, IL-10, IL-12, Arg, MMR, and Hmox1 were determined by qPCR. *, 


































































































































































































































































Figure 3.4: Ly6Chi monocytes increase expression of several genes responsible for iron 
metabolism following a transfusion of old RBCs 
Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old RBCs. (A) At the 
indicated time points, SpiC expression at various time points post-transfusion was determined 
by qPCR. RNAseq was also performed on Ly6Chi monocytes that had been isolated by FACS 
following transfusion with either fresh or old RBCs. (B) Principal component analysis of gene 
expression data comparing Ly6Chi monocytes isolated from 3 mice that received a transfusion 
of old RBCs where the monocytes either ingested or did not ingest RBCs (Old RBC+; Old RBC-
) with Ly6Chi monocytes from 3 mice that received a transfusion of fresh RBCs. (C) Comparative 
gene expression levels for selected genes involved in iron metabolism. (D) List of GO pathways 
upregulated in Ly6Chi monocytes that ingested old RBCs, relative to Ly6Chi monocytes from 
mice that received fresh RBCs. For the remaining panels, wild-type C57BL/6 mice were 
transfused with 350 μl of PBS or old RBCs with an FDR cutoff of 0.05. P < 0.0001; ANOVA with 
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Figure 3.5: RPMs ingest transfused IgG-RBCs and heat-damaged RBCs 
Wild-type C57BL/6 mice were transfused with fresh GFP+ RBCs, IgG-RBCs, or heat-
damaged RBCs. Mice were then sacrificed at 2 hours post-transfusion. Frequency of GFP+ RBC 
phagocytosis in the spleen at 2 hours post-transfusion. Data are representative of 4 
experiments with at least 3 mice per group. ***, p < 0.001; ****, p <0.0001; ANOVA with Tukey 





Transfused old RBCs localize in the marginal zone of the spleen 
As we previously demonstrated the extensive role of RPMs in clearing old RBCs, we 
sought to investigate whether the macrophages in the marginal zone were also involved. The 
spleen has an important role in constantly filtering the blood that circulates throughout the body. 
This filtration occurs in the spleen’s marginal zone and red pulp. Macrophages identified by the 
expression of CD169 (Sialoadhesin; Siglec-1) are located the sub-capsular sinus and the 
marginal sinus, which are both sites of antigen entry.(281) As such, these CD169+ 
macrophages are important in the process of removing pathogens and preventing the spread of 
infection(282–285); they also stimulate several lymphoid cell types to promote innate host 
defense.(286–289) Other important cells in the marginal zone are SIGN-R1+ marginal zone 
macrophages (MZM). SIGN-R1 is a C-type lectin that is highly expressed in a subpopulation of 
MZMs. SIGN-R1 functions in vivo as a pathogen recognition receptor, allowing MZMs to capture 
blood-borne antigens, which are rapidly internalized and targeted to lysosomes for 
processing.(202, 290)  
To examine the marginal zone of the spleen, we used microscopy to identify both the 
localization of transfused RBCs and marginal zone structures. To generate fluorescent RBCs 
that could be easily imaged by microscopy, we labeled RBCs in vivo, as described in the 
Materials and Methods section. The fluorescent RBCs used for these experiments were labeled 
with CSFE and were not damaged during the labeling process. This is likely due to us allowing 
the RBCs to continue to circulate in the mouse for at least 24 hours after the dye has been 
injected. This enables damaged RBCs to be removed by this mouse’s own phagocyte system. 
Following labeling, blood was collected, leukoreduced, packed, and used “fresh” or after 12-14 
days of storage (i.e., “old”) under conditions mimicking those in clinical blood banks. At 5 hours 
after transfusing 200 µl of PBS, or fresh or old packed RBCs into recipients, mice were 
sacrificed and spleens harvested. Tissue sections were stained for SIGN-R1 and CD169 to 
identify macrophages that reside in the marginal zone by immunofluorescence microscopy.  
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SIGN-R1+ and CD169+ cells clearly line the marginal zone in the spleens of recipient 
mice, though the stains do not overlap completely (Fig 3.6). Fluorescent RBCs, displayed in red 
(Fig 3.6), clearly localized to the SIGN-R1+ and CD169+ regions of the spleen. Several SIGN-
R1+ and CD169+ cells appear to contain fluorescent RBCs within their cell boundaries, 
suggesting that erythrophagocytosis occurs in these cell populations. However, despite the 
presence of labeled RBCs in the marginal zone, the vast majority of old RBCs localize to the red 
pulp, likely reflecting their internalization by RPMs; this further supports the finding the RPMs 





Figure 3.6: Transfused old RBCs localize to the marginal zone containing CD169+ and 
SIGN-R1+ macrophages  
Wild-type C57BL/6 mice were transfused with 200 μl old CSFE+ RBCs that were labeled 
in vivo in donors. Recipients were sacrificed at 1 hour post-transfusion. Frozen tissue sections 
were stained for CD169 (green) and SIGN-R1 (blue). Overlays display the localization of old 
transfused RBCs (red) with macrophages in the marginal zone. A)10X and B) 20X 
magnifications are shown.  
CD169 SIGN-R1 RBCs
CD169 + RBCs SIGN-R1 + RBCs
CD169 SIGN-R1 RBCs




Bone marrow macrophages clear damaged or opsonized RBCs from the circulation  
After examining erythrophagocytosis in the spleen, we examined whether bone marrow 
macrophages participated in clearing transfused old RBCs. Although bone marrow 
macrophages are important in erythropoiesis, their relative contribution to the phagocytosis of 
mature RBCs is not completely clear. In addition, although previous studies identified some 
erythrophagocytosis in the bone marrow (291), we wanted to examine this further in the context 
of transfused storage-damaged RBCs. 
 To this end, wild-type C57BL/6 mice were transfused with fluorescent, storage-damaged 
or fresh RBCs, obtained from UBC-GFP donor mice. After 2 hours, recipients were sacrificed, 
bone marrow was harvested, and cells were analyzed by flow cytometry. An F4/80hi, Cd11blo, 
VCAM1+ macrophage population ingested old RBCs, as compared to fresh RBCs (3.88%; Fig 
3.7). This macrophage population also cleared IgG-coated RBCs and heat-damaged RBCs (Fig 
3.8). Additionally, some VCAM-1+, F4/80hi, CD11blo bone marrow macrophages also cleared old 
transfused RBCs.  
 In contrast to the spleen, Ly6Chi monocytes (Ly6Chi, CD11b+, CD115+, Ly6G-) in the 
bone marrow did not ingest old RBCs, IgG-coated RBCs, or heat-damaged RBCs (Fig 3.8). In 
addition, circulating Ly6Chi monocytes did not ingest old RBCs (Fig. 3.9), suggesting that 
something specific to the splenic microenvironment enables or induces Ly6Chi monocytes to 
participate in this type of erythrophagocytosis. Finally, granulocytes in the bone marrow (Fig 3.8) 
or blood (Fig 3.9) did not exhibit erythrophagocytosis of storage- or heat-damaged RBCs, or of 




Figure 3.7: VCAM-1+, F4/80hi bone marrow macrophages ingest transfused old RBCs 
(A) Gating strategy for identifying bone marrow macrophages (VCAM-1+, F4/80hi, 
CD11blo) that phagocytose transfused GFP+ RBCs. (B) Frequency of phagocytosis of old RBCs 
at 2 hours post-transfusion by bone marrow macrophages, Ly6Chi monocytes, and granulocytes; 
although macrophages ingest some transfused RBCs, no such events are seen with Ly6Chi 
monocytes or granulocytes. Data are representative of 3 experiments with at least 3 mice per 




Figure 3.8: Bone marrow macrophages ingest transfused IgG-coated RBCs and heat-
damaged RBCs 
Wild-type C57BL/6 mice were transfused with fresh GFP+ RBCs, IgG-coated RBCs, or 
heat-damaged RBCs. Mice were then sacrificed at 2 hours post-transfusion. The frequency of 
GFP+ RBC phagocytosis at 2 hours post-transfusion in the bone marrow was determined using 
flow cytometry. Data are representative of 4 experiments with at least 3 mice per group. ***, p < 





Figure 3.9: Circulating Ly6Chi monocytes do not ingest old, storage-damaged RBCs 
The frequency of ingested GFP+ RBCs in circulating Ly6Chi monocytes and granulocytes 
at 2 and 24 hours post-transfusion was determined by flow cytometry. Data are representative 
of 3 experiments with at least 3 mice per group. ns, not significant; ANOVA with Tukey or Sidak 
multiple comparison test.  
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Section 3.3: Discussion 
 Data obtained using a mouse model of RBC storage and transfusion demonstrated that 
RPMs exhibit a substantial amount of erythrophagocytosis of transfused old RBCs, IgG-coated 
RBCs, or heat-damaged RBCs. Splenic Ly6Chi monocytes also ingested transfused old or IgG-
coated RBCs. Although the level of phagocytosis of splenic monocytes was substantially lower 
than that of RPMs, they nonetheless contribute to clearing “effete” RBCs from the circulation. 
Furthermore, following ingestion of old RBCs, Ly6Chi monocytes exhibited increases in 
expression in genes related to iron metabolism, with a higher level of expression observed in 
Ly6Chi monocytes that had specifically ingested old RBCs, as opposed to just being present in 
the mice that received a transfusion of old RBCs. 
CD169+ and SIGN-R1+ macrophages in the marginal zone of the spleen also cleared 
transfused old RBCs; nonetheless, based on imaging data, the transfused old RBCs co-
localized to a greater extent in the red pulp as compared to the marginal zone, further 
emphasizing the role of RPMs in RBC clearance.    
 Macrophages residing in the bone marrow also ingested transfused old, IgG-coated, or 
heat-damaged RBCs. However, Ly6Chi monocytes in the bone marrow and blood did not clear 
these types of RBCs. This suggests that there are conditions specific to the splenic 
microenvironment that enable this monocyte population to clear these RBCs. It is important to 
note that erythrophagocytosis also occurs in the liver, typically mediated by Kupffer cells.(292) 
Taken together, these data suggest that multiple different phagocyte populations are involved in 





CHAPTER 4: Increased erythrophagocytosis induces ferroptosis in macrophages 
Adapted and expanded significantly from: Youssef LA, Rebbaa A, Pampou S, Weisberg SP, 
Stockwell BR, Hod EA, Spitalnik SL. Increased erythrophagocytosis induces ferroptosis in red pulp 
macrophages in a mouse model of transfusion. Blood. 2018 Jun 7;131(23):2581-2593. 
 
Macrophages play important roles in recycling iron derived from the clearance of RBCs. 
They are also a critically important component of host defense, protecting against invading 
pathogens. However, the effects on macrophage biology of acutely ingesting large numbers of 
RBCs are not completely understood. To investigate this issue, we used a mouse model of RBC 
transfusion and clearance, which mimics the clinical setting. In this model, transfusions of 
refrigerator storage-damaged (i.e., “old”) RBCs led to increased erythrophagocytosis by splenic 
RPMs. This robust erythrophagocytosis induced ferroptosis, an iron-dependent form of cell 
death, in RPMs. This was accompanied by increases in reactive oxygen species and lipid 
peroxidation in vivo, which were reduced by treatment in vitro with ferrostatin-1, a ferroptosis 
inhibitor. In conclusion, these findings may be clinically relevant to pathological conditions that 
can arise as a result of increased erythrophagocytosis, such as transfusion-related 
immunomodulation (TRIM) and impaired host immunity.  
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Section 4.1: Introduction 
Erythrophagocytosis of senescent RBCs is important for the physiological iron recycling 
necessary for normal erythropoiesis. In humans, RBCs have a lifespan of ~120 days, before 
being recycled by hepatic and splenic phagocytes. However, multiple disorders lead to a 
shortened RBC lifespan and increased or pathologic erythrophagocytosis, including malaria 
(270), IgG-mediated hemolytic transfusion reactions (271), warm-type autoimmune hemolytic 
anemia (272), and acute hemolytic crises in sickle cell disease or glucose-6-phosphate 
dehydrogenase deficiency (273). RBC transfusions can also induce a rapid increase in 
erythrophagocytosis due to the acute clearance of refrigerator storage-damaged RBCs (129). 
Given the critically important role that phagocytes play in host defense, if acutely increased 
erythrophagocytosis harmed phagocyte function, this could predispose the host to TRIM and 
harmful infectious consequences.  
Following phagocytosis of “effete” RBCs, by any recognition mechanism, their 
hemoglobin is degraded in the lysosomal system and a proportion of the resulting inorganic iron 
is released from the phagocyte into plasma by ferroportin; this iron is subsequently transported 
through the circulation by transferrin. However, if “free” iron is present in plasma or cytosol, it is 
highly reactive and can participate in multiple redox reactions. For example, Fe2+ reacts with 
peroxides to produce hydroxyl and lipid alkoxy radicals through the Fenton reaction, thereby 
producing multiple reactive oxygen species (ROS) and lipid peroxidation products (293). Thus, 
to minimize its adverse effects, iron is typically bound by an array of chaperones. For example, 
cytosolic ferritin assists in storing iron intracellularly, converting reactive Fe2+ into more stable, 
oxidized Fe3+ (294, 295).  
Nonetheless, in certain clinical situations (see above), macrophages are subjected to an 
acute and substantial increase in erythrophagocytosis. Following increases in 
erythrophagocytosis and intracellular heme levels, macrophage cell loss is observed. (292, 296) 
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However, the causes of the effects of this robust erythrophagocytosis on macrophages are still 
not completely clear, but may result from the large iron load that is abruptly delivered to these 
cells. In this context, we hypothesized that increased erythrophagocytosis would induce 
macrophage ferroptosis, an iron-dependent form of non-apoptotic cell death originally identified 
in cancer cells (152), but not yet studied in macrophages following erythrophagocytosis. 
Ferroptosis is characterized by increased ROS and lipid peroxidation due to metabolic 
dysfunction (297, 298). If pathologic erythrophagocytosis did, indeed, induce phagocyte cell 
death, this could negatively affect host immunity, particularly with regard to infectious 
pathogens. 
To investigate these issues, we used a mouse model of RBC storage and transfusion 
that closely mimics the human setting, including achieving similar post-transfusion RBC 
recovery and lifespan (278). RBC transfusions are the most common therapeutic intervention in 
hospitalized patients, with ~12 million RBC units administered annually in the United States of 
America (299) for multiple indications (e.g., trauma, surgery, and cancer). Despite clear clinical 
benefits, RBC transfusions are associated with adverse effects, including an increased risk of 
bacterial infection in patients and animal models (253–255, 263–266). In addition, in animal 
models, transfusions of refrigerator storage-damaged RBCs acutely increase circulating levels 
of multiple cytokines (129, 300).  
In our mouse model, transfusions of refrigerator storage-damaged (i.e., “old”) RBCs 
enhanced erythrophagocytosis by splenic RPMs. This robust erythrophagocytosis induced RPM 
ferroptosis, accompanied by increases in ROS and lipid peroxidation in vivo, all of which were 
reduced in vitro by ferrostatin-1, a ferroptosis inhibitor. Following the depletion of these RPMs, 
the remaining RPMs underwent cell division to help restore the population back to homeostasis. 
Nonetheless, before homeostasis is achieved, this RPM depletion could predispose the host to 
adverse consequences (e.g., infection) resulting from defective immune function.   
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Section 4.2: Results 
Enhanced erythrophagocytosis induces increased ROS, lipid peroxidation, and cell death 
in RPMs 
RPM cell numbers substantially decreased by 2 hours after old, as compared to fresh, 
RBC transfusions and did not return to steady-state levels until 2 days post-transfusion (Fig. 
4.1A). This dramatic decrease in RPM cell numbers could be due to an artifact; that is, it may 
result from a phagocytosis-induced decrease in expression of the cell surface markers used to 
identify this population. To address this concern, we used MaFIA mice, which express EGFP 
under the control of the Csfr1 promoter (301). Using a specific strategy (Fig. 4.1B), we gated for 
non-RPM, GFP-expressing cells to quantify the number of remaining cells. By this approach, 
when MaFIA mice were transfused with old, as compared to fresh, RBCs, there was no 
corresponding increase in non-RPM cell numbers to indicate that the RPMs were not being 
depleted, but instead had decreased their surface expression of these identifying markers (Fig. 
4.1C); this confirms that RPM cell numbers do dramatically decrease following old RBC 
transfusions. In addition, no decrease in RPM cell numbers was observed in mice transfused 
with supernatant isolated from old stored RBCs, indicating that this cell loss is mediated by 
erythrophagocytosis, not by passive infusion of free hemoglobin, heme, or other soluble 
compounds (Fig. 4.1D). In addition, RPMs that ingested RBCs displayed increased Annexin V 
cell surface expression by 2 hours post-transfusion (11.27%), which peaked at 5 hours post-
transfusion (25.96%), and returned to steady-state levels by 1 day post-transfusion (Fig. 4.2A); 
thus, erythrophagocytosis induces phosphatidylserine exposure on RPMs, which is associated 
with various types of cell death. Furthermore, by qPCR analysis, RPMs exhibited a 7.9-fold 
increased accumulation of prostaglandin-endoperoxide synthase 2 (PTGS2) mRNA, the gene 
that encodes the cyclooxygenase-2 (COX-2) protein (Fig. 4.2B); an increase in PTGS2 mRNA 
levels is frequently induced in cells undergoing ferroptosis, and this process occurs downstream 
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of lipid peroxidation (298, 302). In addition, by 2 hours after transfusion with old, as compared to 
fresh, RBCs, there were increases is DCF fluorescence, suggestive of ROS production (16.1% 
to 24.1%; Fig. 4.2C), and C11-Bodipy fluorescence, indicative of lipid peroxidation (2.0% to 
19.8%; Fig. 4.2D); these phenomena are both observed concomitantly with ferroptosis, with lipid 




Figure 4.1: RPMs are depleted following a transfusion of old RBCs  
(A) Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old RBCs and 
sacrificed at defined time points. Splenic RPM cell numbers were quantified post-transfusion. 
Old RBC transfusions induced a substantial decrease in RPMs by 2 hours post-transfusion, the 
levels of which returned to baseline 2 days later. (B) The gating strategy first selects for splenic 
nucleated non-RPM cells, which thereby selects for GFP+ (Csfr1/CD115+) cells; this is followed 
by gating out B cells, granulocytes, DCs, monocytes, and RPMs. The remaining cells were 
quantified to determine changes following transfusions of old, as compared to fresh, RBCs. (C) 
MaFIA mice were transfused with 350 μl of fresh or old RBCs and sacrificed 5 hours post-
transfusion. Total non-RPM nucleated cell numbers in the spleen were quantified, showing no 
differences. (D) Wild-type C57BL/6 mice were infused with PBS or supernatant from 350 μl of 
an old RBC blood bank and RPM cell number was quantified 5 hours post-transfusion. *, p 
<0.05; ***, p <0.001; ****, p <0.0001; ANOVA with the Sidak multiple comparisons test. Data are 




Figure 4.2: Transfusions of old RBCs induce oxidative stress and PTGS2 expression in 
RPMs 
Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old RBCs and sacrificed 
at defined time points. Splenic RPM cell numbers were quantified post-transfusion. Old RBC 
transfusions induced a substantial decrease in RPMs by 2 hours post-transfusion, the levels of 
which returned to baseline 2 days later. (A) Annexin V staining of RPMs following transfusion of 
old and fresh RBCs. (B) Upregulation of PTGS2 mRNA expression in RPMs after old RBC 
transfusions. Increases in ROS production (C) and lipid peroxidation (D) in RPMs following 
transfusions of old RBCs. **, p <0.01; ***, p <0.001; ****, p <0.0001; ANOVA with the Sidak 
multiple comparisons test. PTGS2 gene expression analysis was analyzed for significance 




Following depletion, there is local RPM proliferation to help restore the population back 
to homeostasis  
RPMs are capable of local self-maintenance by cell division (303, 304). Thus, Ki67 
staining of RPMs at various time points following old RBC transfusion revealed that, soon after 
transfusion-induced RPM cell loss, the remaining RPMs begin to proliferate, thereby helping 
replace the diminished RPM population (Fig. 4.3A). To determine the relative importance of 
resident RPMs in maintaining the splenic RPM population following transfusions of old RBCs, 
we used CCR2-/- mice, which have Ly6Chi monocytes that do not express CCR2. As a result, 
Ly6Chi monocytes in CCR2-/- mice are confined to the bone marrow and cannot migrate to the 
spleen in response to CCL2 and/or CCL7 (305); thus, they would be unable to supplement the 
RPM population that had been depleted by erythrophagocytosis (Fig. 4.3B,C). In this model, 
splenic resident RPMs in CCR2-/- mice proliferated following the cell death induced by old RBC 
transfusions, thereby completely regenerating themselves back to steady-state levels without 
requiring supplementation by circulating Ly6Chi monocytes (Fig. 4.3D,E). 
 
Macrophages undergo ferroptosis following enhanced erythrophagocytosis 
Ferroptosis, in addition to being characterized by increased ROS production, lipid 
peroxidation, and PTGS2 mRNA accumulation, can be rescued by ferrostatin-1 (Fer-1), a 
ferroptosis-specific inhibitor (297, 306). As Fer-1 is not stable in mouse plasma, it is exceedingly 
difficult to use in vivo. Therefore, we used a cell culture model of enhanced erythrophagocytosis 
involving exposure of macrophages to IgG-coated RBCs, which markedly increases 
erythrophagocytosis in vitro in comparison to using old RBCs (307). By this approach, J774 
murine macrophages and primary BMDMs, the latter of which were differentiated for at least 7 
days to establish a VCAM-1+, F4/80hi cell population (Fig. 4.4A-C), demonstrated substantial 
phagocytosis of IgG-coated RBCs (Fig. 4.5A,B). Following this increased erythrophagocytosis, 
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J774 cells exhibited increased ROS and lipid peroxidation, which were both reduced by prior 
treatment with Fer-1 (Fig. 4.5C,D). Fer-1 induced similar decreases in ROS and lipid 
peroxidation in BMDMs (Fig. 4.5E,F). Finally, we used a high-throughput viability assay with 
BMDMs that were treated with vehicle control or Fer-1 before ingesting RBCs. By 6 hours after 
incubation with IgG-coated RBCs, BMDMs receiving vehicle control demonstrated substantial 
cell death, which was effectively prevented by Fer-1 (25.0% to 12.0%; Fig. 4.5G). Furthermore, 
BMDMs and J774 cells were sensitive to erastin, RSL3, and imidazole ketone erastin (IKE), 
which induce ferroptosis in other cell lines (Fig. 4.6A,B)(297, 308), indicating their susceptibility 
to ferroptosis. Taken together, these results indicate that ferroptosis plays a major role in 




Figure 4.3: Splenic RPMs exhibit local self-maintenance following old RBC transfusion-
induced cell death 
(A) Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old RBCs and 
sacrificed at defined time points. Splenic RPMs were stained with Ki67, demonstrating 
increased proliferation at 1-2 days after old RBC transfusions, as compared to RPMs from mice 
that received fresh RBCs. Histogram (left) of Ki67 staining at 1 day post-transfusion. (B) Ly6Chi 
monocyte cell numbers were quantified in the blood of CCR2-/- mice, demonstrating their 
absence. (C) Ly6Chi monocyte cell numbers were quantified in the spleens of CCR2-/- mice, 
demonstrating their absence. (D) The splenic RPM population in CCR2-/- mice is reduced by 5 
hours after transfusions of old RBCs, but restored by 2 days post-transfusion. (E) By Ki67 
staining, RPMs in CCR2-/- mice proliferate following transfusion of old RBCs, relative to RPMs in 
mice that received fresh RBCs. Histogram (left) of Ki67 at 2 days post-transfusion. **, p <0.01; 
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Figure 4.4: Bone marrow cells cultured in the presence of m-CSF differentiate into a 
uniform VCAM-1+ and F4/80hi population 
Bone marrow was harvested from wild-type C57BL/6 mice and cultured in the presence 
of M-CSF (20 ng/ml) for defined times to determine when the cell population uniformly 
expressed VCAM-1 and F4/80. (A) Representative dot plots (the percentages of double-positive 
cells are indicated), (B) frequency of VCAM-1+, F4/80hi macrophages, and (C) overall VCAM-1 
expression are shown. Data are representative of 3 independent experiments. ****, p <0.0001; 
ANOVA with the Dunnett multiple comparisons test. 
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Figure 4.5: Enhanced erythrophagocytosis induces macrophage ferroptosis in vitro 
Bone marrow was harvested from wild-type C57BL/6 mice and cultured in the presence 
of M-CSF (20 ng/ml) for defined times to determine when the cell population uniformly 
expressed VCAM-1 and F4/80. (A) Representative dot plots (the percentages of double-positive 
cells are indicated), (B) frequency of VCAM-1+, F4/80hi macrophages, and (C) overall VCAM-1 
expression are shown. BMDMs and J774 cells were plated 24 hours prior to the experiments 
and then incubated with PBS, fresh RBCs, or IgG-coated RBCs, which were labeled with 
CellTrace Far Red. The amount of erythrophagocytosis in (A) J774 cells and (B) BMDMs was 
quantified by flow cytometry. J774 cells (C,D)  and BMDMs (E,F) were treated with vehicle 
control or 100 μM Fer-1 and exposed to IgG-opsonized RBCs; they were then analyzed for ROS 
(C,E) and lipid peroxidation (D,F). BMDM cell viability was quantified following incubation with 
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IgG-coated RBCs or PBS, and with vehicle control or 100 μM Fer-1 for 6 hours; enhanced 
erythrophagocytosis induced substantial cell death, which was ameliorated by Fer-1 (G). Data 
are representative of 3 independent experiments. *, p <0.05; ***, p <0.001; ****, p <0.0001; 










Figure 4.6: BMDMs are susceptible to cell death after treatment with ferroptosis inducers 
Twenty-four hour exposure to erastin (20 μM), RSL3 (1 μM), or IKE (20 μM), which are 
potent ferroptosis inducers, led to J774 (A) and BMDM cell loss (B). Data are representative of 





Section 4.3: Discussion  
In our mouse model, RPMs were the predominant splenic population that ingest old, 
transfused RBCs (Fig. 3.1). Following this enhanced erythrophagocytosis, RPM cell numbers 
dramatically declined (Fig. 4.1A), accompanied by increased ROS, lipid peroxidation, and 
PTGS2 gene expression in these cells (Fig. 4.2B-D). Our data in vitro and in vivo strongly 
suggest that this decline in RPM cell numbers was due to ferroptosis (Fig. 4.1A, 4.2B-D, 4.5C-
G), induced by the substantial increase in erythrophagocytosis experienced by these cells. With 
local cell division of remaining RPMs, the RPM population was able to return to pre-transfusion 
numbers by 2 days. Furthermore, CCR2-deficient mice were fully able to re-populate the spleen 
(Fig. 4.3D), suggesting that an influx of circulating Ly6Chi monocytes may not be required to 
restore this population of macrophages in the spleen.  
Ferroptosis is an iron-dependent form of non-apoptotic cell death (297). Several 
compounds induce ferroptosis, including erastin (297), IKE, RSL3 (309), and buthionine 
sulfoximine (298). One limitation of Fer-1, a specific inhibitor of ferroptosis, is that it is not stable 
in mouse plasma, restricting our rescue experiments using this compound to an in vitro model. 
Ferroptosis is characterized by the accumulation of lipid peroxidation products and lethal ROS 
derived from iron-dependent reactions. To date, ferroptosis has been described in cancer cells 
(297), kidney tubule cells (306, 310, 311), fibroblasts (310, 312), neurons (313), and T cells 
(314), but its occurrence in macrophages is not well studied. As macrophages play important 
physiological roles in iron metabolism and recycling, the occurrence of ferroptosis (i.e., iron-
dependent cell death) in these cells is especially relevant. Normal physiological RBC and iron 
recycling, where each macrophage clears, on average, one RBC per day, does not appear to 
have any adverse effects on macrophage function. In addition, in response to some degree of 
enhanced erythrophagocytosis, macrophages can respond homeostatically by increasing their 
expression of, for example, HO-1 and ferritin, which allow the cell to handle the increased heme 
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and iron load, respectively, while still protecting it from severe oxidative stress (137). As might 
be expected, there is an increase in Hmox-1 expression, the mRNA encoding HO-1, soon after 
transfusion of old RBCs (Fig. 3.3). However, it is likely, given the number of RBCs that are 
rapidly ingested, and the accompanying amount of heme iron that needs to be rapidly 
metabolized and detoxified, that the rate and amount of this increase in Hmox-1 production is 
insufficient to prevent cell death in this setting. Thus, we believe that the erythrophagocytosis-
mediated ferroptotic cell death occurred too rapidly to be prevented by appropriate increases in 
Hmox-1 gene expression, and subsequent HO-1 enzyme synthesis, thereby allowing 
catastrophic cell damage. Therefore, our results suggest that substantial erythrophagocytosis 
can exceed these homeostatic mechanisms, leading to cell death. Furthermore, we would 
expect worse clinical outcomes in mouse models using exchange transfusions with storage-
damaged RBCs (e.g. as in hemorrhage-resuscitation models), as compared to the “top-load” 
transfusions used in our extensively evaluated model (129, 278), which could complicate and 
confound the outcomes observed. 
Given the importance of phagocytes in host defense, including innate, adaptive, and 
nutritional immunity, it will be important for future studies to determine whether the dramatic, 
acute, ferroptosis-induced decreases in RPM cell numbers interfere with critical splenic 
functions, such as clearing circulating pathogenic bacteria during infection and asymptomatic 
bacteremia. Because an increased incidence of infection following transfusions can exemplify 
TRIM (315), it is legitimate to question whether the effects on RPM cell number seen here 
represent at least one mechanism underlying TRIM. In addition, given the increased prevalence 
of dangerous bacterial infections in humans with hemolytic disorders, such as in sickle cell 
disease (316) and malaria (317), it will also be important to determine whether immune 
dysfunction due to erythrophagocytosis-induced phagocyte ferroptosis contributes to these 
outcomes. Finally, if splenic RPM ferroptosis occurs in other clinically-relevant settings 
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exhibiting acute, dramatic increases in erythrophagocytosis, such as IgG-mediated hemolytic 
transfusion reactions (271), warm-type autoimmune hemolytic anemia (272), and acute 
hemolytic crises in glucose-6-phosphate dehydrogenase deficiency (273), it could significantly 




CHAPTER 5: Splenic Ly6Chi monocytes mediate an inflammatory response to transfused 
RBCs 
Adapted and expanded significantly from: Youssef LA, Rebbaa A, Pampou S, Weisberg SP, 
Stockwell BR, Hod EA, Spitalnik SL. Increased erythrophagocytosis induces ferroptosis in red pulp 
macrophages in a mouse model of transfusion. Blood. 2018 Jun 7;131(23):2581-2593. 
 
Previous data identified increased circulating levels of CCL2 following a transfusion of 
old RBCs.(129) CCL2 or, equivalently, monocyte chemoattractant protein-1 (MCP-1) is a 
chemokine that is released during an inflammatory response and can induce a reserve of 
inflammatory monocytes that resides in the bone marrow to emigrate from there towards various 
sites of inflammation, where the monocytes can then undergo differentiation into other types of 
immune cells, depending on the response. As such, we wanted to determine whether a 
corresponding influx of circulating monocytes occurred as part of the inflammatory response to 
a transfusion of old RBCs.   
Using our previously described mouse transfusion model, we found that old RBC 
transfusions induced RPM-dependent chemokine expression by splenic Ly6Chi monocytes, 
which signaled Ly6Chi monocyte migration from bone marrow to the spleen, where these cells 
subsequently differentiated into RPMs. The combination of cell division among remaining 
splenic RPMs, along with the influx of bone marrow-derived Ly6Chi monocytes, suggests that, 
following RPM depletion induced by robust erythrophagocytosis, there is a coordinated effort to 
restore homeostasis of the RPM population by local self-maintenance and by contributions from 




Section 5.1: Introduction 
Monocytes are a subset of circulating white blood cells that can further differentiate into 
a range of tissue macrophages and DCs.(318, 319) Bloodstream monocytes are derived from 
precursors in the bone marrow(320) and are subdivided into subsets that differ in their response 
to various stimuli, including trafficking and innate immune receptor expression, as well as 
differentiation following stimulation with cytokines or microbial molecules.(318) As such, 
monocytes can be identified as members of distinct subsets based on their chemokine receptor 
expression and the presence of specific surface molecules.(170, 171) In mice, expression of 
Ly6Chi, CD11bhi, CD115+, CCR2hi identifies one subset of monocytes, referred to as 
“inflammatory” or “Ly6Chi” monocytes. Inflammatory monocytes represent approximately 2–5% 
of circulating white blood cells at homeostasis and are rapidly recruited to sites of infection and 
inflammation.(321) CCR2 deficiency (e.g., in CCR2 knockout mice) markedly reduces Ly6Chi 
monocyte trafficking to sites of inflammation, which highlights the important role for this 
chemokine receptor in trafficking of these monocytes.(322, 323)  
Prior studies in mice and dogs identified increased circulating levels of multiple 
inflammatory cytokines after transfusions of refrigerator storage-damaged RBCs.(129, 300) One 
chemokine identified was MCP-1, also known as CCL2. CCL2 is the ligand for CCR2, which is 
expressed by several cell types, including Ly6Chi (i.e., inflammatory) monocytes. One reserve 
site of Ly6Chi monocytes is the bone marrow, from which they emigrate into the circulation in a 
CCR2-dependent manner to traffic to sites of inflammation. Because the spleen is a primary site 
of RBC clearance, we aimed to identify the splenic cells responsible for producing CCL2 
following transfusions of storage-damaged RBCs. Although RPMs were the major cell type 
responsible for clearing transfused refrigerator-damaged RBCs, we found that splenic Ly6Chi 
monocytes, but not RPMs, produced CCL2. Thus, the splenic reserve of inflammatory 
monocytes produced an inflammatory response following a phagocytosis-mediated acute 
hemolytic event. Increased numbers of circulating inflammatory monocytes post-transfusion, 
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and reduced numbers in the bone marrow, suggest that these cells emigrated from the bone 
marrow, perhaps in response to CCL2 signaling. Thus, one possible mechanism explaining our 
results is that erythrophagocytosis in the spleen induces an inflammatory response, triggering 
splenic inflammatory monocytes to synthesize CCL2 and release it into the circulation; CCL2 
then binds CCR2 on bone marrow inflammatory monocytes, causing their egress into the 
circulation and ultimate trafficking to the spleen. This response by splenic Ly6Chi monocytes 
appears to depend on the RPMs in the spleen that are simultaneously undergoing ferroptosis, 
due to the absence of this response in Spic-/- mice that lack RPMs. Furthermore, Ly6Chi 
monocytes that had migrated from the bone marrow to the spleen then differentiated into RPMs, 
demonstrating that they aid in supplementing the depleted population of RPMs that occurs after 
a transfusion with old RBCs.  
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Section 5.2: Results 
Old RBC transfusions induce Ly6Chi inflammatory monocyte trafficking to the spleen 
Ly6Chi monocytes are known to emigrate from the bone marrow in response to specific 
chemokines, including CCL2 and CCL7, which can engage their cell surface receptor: CCR2 
(319, 324, 325). Old, but not fresh, RBC transfusions induced a dramatic increase in circulating 
Ly6Chi monocytes in recipients, which peaked at 5 hours post-transfusion and returned to 
steady-state levels by 24 hours post-transfusion (Fig. 5.1A,B). This increase in Ly6Chi 
monocytes coincided with a concomitant decrease in the number of these cells in the bone 
marrow (Fig. 5.1A,C). The number of Ly6Chi monocytes in the spleen also increased at 5 hours 
post-transfusion and returned to steady-state levels by 24 hours post-transfusion (Fig. 5.1A,D). 
Based on Ki67 staining, splenic Ly6Chi monocytes did not actively proliferate post-transfusion 
(Fig. 5.2). These findings suggest that the post-transfusion increase in splenic Ly6Chi 
monocytes resulted from migration of these cells to the spleen from the bone marrow, not from 
proliferation in situ of pre-existing splenic Ly6Chi monocytes.   
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Figure 5.1: Ly6Chi monocytes emigrate from the bone marrow and home to the spleen 
after transfusion of old RBCs 
Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old RBCs and sacrificed 
at defined time points. (A) Flow plots depict increases in Ly6Chi monocytes in the blood and 
spleen and a decrease in the bone marrow at 5 hours post-transfusion. (B) Quantification of 
circulating Ly6Chi monocytes at defined time points demonstrating increased levels at 5 hours 
post-transfusion. (C) Quantification of bone marrow Ly6Chi monocytes demonstrating decreased 
levels at 5 hours post-transfusion. (D) Splenic Ly6Chi monocyte levels increase substantially at 5 
hours post-transfusion. Data are representative of 3 experiments with at least 3 mice per group. 




Figure 5.2: The increase in splenic Ly6Chi monocytes is not due to cell division of local 
monocytes  
Wild-type C57BL/6 mice were transfused with 350 μl of fresh or old RBCs and sacrificed 
at defined time points. Histogram of Ki67 staining of splenic Ly6Chi monocytes at 5 hours post-
transfusion. Data are representative of 3 experiments with at least 3 mice per group. **, p <0.01; 




Splenic Ly6Chi monocytes upregulate CCL2 and CCL7 mRNA expression in an RPM-
dependent fashion following enhanced erythrophagocytosis 
To understand the influx of Ly6Chi monocytes into the circulation, we examined whether 
a splenic cell population was a source of chemokines that might signal this migration. To this 
end, in recipients of old RBC transfusions, RPMs did not upregulate expression of CCL2 or 
CCL7 mRNA, and actually downregulated their expression by 1 day post-transfusion (Fig. 5.3). 
This was confirmed using CCL2-GFP reporter mice (Fig. 5.4). In contrast, by 5 hours after 
transfusion of old RBCs, Ly6Chi monocytes dramatically increased their expression of CCL7 and 
CCL2 mRNA (20.55-fold and 7.00-fold, respectively), before returning to steady-state levels 
(Fig. 5.3). This was surprising, because a relatively low percentage of Ly6Chi monocytes 
actually phagocytose old RBCs, as compared to RPMs (Fig. 3.1). Using CCL2-reporter mice, 
there were no increases in CCL2 expression in Ly6Chi monocytes in blood or bone marrow, in 
contrast to those in the spleen, further highlighting an important role for neighboring RPMs in 
this phenomenon (Fig. 5.5). 
Given the robust erythrophagocytosis by RPMs, we sought to determine whether 
expression of CCL2 and CCL7 mRNA by Ly6Chi monocytes required RBC clearance by RPMs. 
To address this, we used Spic-/- mice, which lack Spi-C, a transcription factor that selectively 
controls RPM development, (197) and, therefore, lack RPMs (Fig. 5.6A,B). Spic+/+ and Spic-/- 
mice were transfused with fresh or old RBCs, and splenic Ly6Chi monocytes were isolated by 
FACS at 5 hours post-transfusion. RPMs in Spic+/+ mice effectively ingested old RBCs (Fig. 
5.6C). No difference in the amount of erythrophagocytosis by Ly6Chi monocytes was observed 
in the presence or absence of RPMs, indicating that RPMs are not required for 
erythrophagocytosis by these monocytes (Fig. 5.6D). However, in the absence of RPMs, Ly6Chi 
monocytes exhibited markedly reduced CCL2 and CCL7 mRNA expression following old RBC 
transfusions (Fig. 5.6E). This indicates that CCL7 and CCL2 mRNA expression by Ly6Chi 
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monocytes depends upon erythrophagocytosis by RPMs, suggesting that an “upstream 





Figure 5.3: CCL2 and CCL7 mRNA expression by splenic Ly6Chi monocytes following 
enhanced erythrophagocytosis  
At defined time points after transfusing wild-type recipients with 350 μl of fresh or old 
RBCs, splenocytes were isolated by FACS, and CCL2 and CCL7 mRNA expression were 
measured by qPCR in (A) RPMs and (B) Ly6Chi monocytes; these data show that, after old 
RBC transfusions, expression of these chemokines did not change, or even decreased, in 
RPMs, whereas they both increased substantially in Ly6Chi monocytes at 5 hours post-
transfusion. *, p <0.05; **, p <0.01; ***, p <0.001; ANOVA with Sidak or Tukey multiple 






Figure 5.4: Splenic Ly6Chi monocytes, but not RPMs, express CCL2  
CCL2-GFP reporter mice were transfused with 200 μl of PBS, fresh GFP+ RBCs, or old 
GFP+ RBCs, and then sacrificed at 2 hours post-transfusion. (A) Gating strategy for splenic 
RPMs and Ly6Chi monocytes along with representative dot plots showing induced CCL2-
promoter-dependent GFP expression; the percentages of cells expressing GFP are provided. 
(B) Frequency of GFP expression, demonstrating upregulation by Ly6Chi monocytes, but not by 
RPMs. ****, p <0.0001; ANOVA with Sidak or Tukey multiple comparisons test or unpaired t 
test. Data are representative of 3 independent experiments, except for Spic+/+ and Spic-/- results, 







Figure 5.5: Ly6Chi monocytes in the blood and bone marrow do not express CCL2  
CCL2-GFP reporter mice were transfused with 200 μl of PBS, fresh RBCs, or old GFP+ 
RBCs, and then sacrificed at 2 hours post-transfusion. (A) Gating strategy for Ly6Chi monocytes 
in the blood and bone marrow, along with (B) representative dot plots showing CCL2-promoter-






Figure 5.6: CCL2 and CCL7 mRNA expression by splenic Ly6Chi monocytes following 
enhanced erythrophagocytosis requires the presence of RPMs  
At defined time points after transfusing wild-type recipients with 350 μl of fresh or old 
RBCs, splenocytes were isolated by FACS, and CCL2 and CCL7 mRNA expression were 
measured by qPCR. (A, B) RPMs (VCAM-1hi, F4/80hi) are absent in Spic-/- mice, as compared to 
Spic+/+ controls. (C) The proportion of RPMs in Spic+/+ recipient mice that ingested old GFP+ 
RBCs. (D) The proportions of Ly6Chi monocytes in Spic+/+ and Spic-/- mice that ingested old 
GFP+ RBCs. (E) Fold regulation of CCL2 and CCL7 mRNA expression, as measured by qPCR, 
in splenic Ly6Chi monocytes from Spic+/+ and Spic-/- mice. *, p <0.05; **, p <0.01; ***, p <0.001; 
****, p <0.0001; ANOVA with Sidak or Tukey multiple comparisons test or unpaired t test. Data 
are representative of 3 independent experiments, except for Spic+/+ and Spic-/- results, which 
were pooled for all experiments. 
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Differentiation of circulating Ly6Chi monocytes after their migration to the spleen aides in 
restoring the depleted RPM population following a transfusion of old RBCs 
GFP+ Ly6Chi monocytes that were adoptively transferred into wild-type recipients prior to 
transfusions with old RBCs migrated to the spleen by 2 hours-post-transfusion (Fig. 5.7), further 
demonstrating that circulating Ly6Chi monocytes traffic to the spleen in this model. By 5 days-
post-transfusion, GFP+ RPMs were observed in the spleen, indicating that the adoptively 
transferred monocytes had differentiated into RPMs (Fig. 5.7); thus, some monocytes that 
emigrate from the bone marrow to the spleen following transfusion of old RBCs eventually 
differentiate into RPMs to supplement the depleted population. These results support prior 
findings that RPMs are replaced by monocytes following heme-induced depletion (198). 
However, RPMs are also capable of local self-maintenance by cell division (303, 304). Indeed, 
Ki67 staining of RPMs at various time points following old RBC transfusion revealed that, soon 
after transfusion-induced RPM cell loss, the remaining RPMs begin to proliferate, thereby 
helping to replace the diminished RPM population (Fig. 5.7). To determine the relative 
importance of resident RPMs in maintaining the splenic RPM population following transfusions 
of old RBCs, we used CCR2-/- mice, which have Ly6Chi monocytes that do not express CCR2. 
As a result, Ly6Chi monocytes in CCR2-/- mice are confined to the bone marrow and cannot 
migrate to the spleen in response to CCL2 and/or CCL7 (305); thus, they would be unable to 
supplement the RPM population that had been depleted by erythrophagocytosis (Fig. 5.7). 
Using this model, splenic resident RPMs in CCR2-/- mice proliferated following the cell death 
induced by old RBC transfusions, thereby completely regenerating themselves back to steady-




Figure 5.7: Ly6Chi monocytes from the circulation contribute to replenishing the depleted 
RPM population in the spleen 
Bone marrow from UBC-GFP mice was harvested and enriched for Ly6Chi monocytes by 
negative selection. GFP+, Ly6Chi, CD115+, CD11b+ monocytes were then adoptively transferred 
to wild-type C57BL/6 recipients prior to transfusion of the latter with 350 μl of old RBCs. At 2 
hours post-transfusion, GFP+ Ly6Chi monocytes were observed in the spleen. By 5 and 8 days 
post-transfusion, GFP+ RPMs (F4/80hi, VCAM-1hi) were observed in the spleen.  
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Section 5.3: Discussion 
The clearance of storage-damaged transfused RBCs induced increased CCL2 and 
CCL7 mRNA expression by splenic Ly6Chi monocytes (Fig. 5.4); this was accompanied by 
emigration of inflammatory monocytes from the bone marrow into the circulation and then 
homing to the spleen (Fig. 5.1, 5.8), likely a chemotactic response to increased splenic 
expression of these chemokines. Increased CCL2 and CCL7 mRNA expression by splenic 
Ly6Chi monocytes required the presence of RPMs (Fig. 5.7E), likely due to the latter’s clearance 
of old RBCs and subsequent, as yet unidentified, downstream effects. One possibility is that 
dying, ferroptotic RPMs could release heme, which then would then stimulate monocyte CCL2 
and CCL7 expression by signaling through TLR4 (326).  Repopulating the spleen with RPMs 
following erythrophagocytosis-induced cell death resulted from both local cell division of the 
remaining resident RPMs (Fig. 4.3) and differentiation of newly arrived circulating Ly6Chi 
monocytes into RPMs (Fig. 5.8). Although this highlights a coordinated effort among different 
cell types to replenish this depleted splenic cell population, RPMs in CCR2-deficient mice were, 
nonetheless, fully able to re-populate the spleen without requiring an influx of circulating Ly6Chi 
monocytes (Fig. 4.3D). Taken together, this suggests that mice have redundant pathways to 
maintain, or return to, homeostasis in this setting. Indeed, although both RPM cell division and 
monocyte migration occur after erythrophagocytosis-mediated RPM ferroptosis, these 
responses are most likely independent of each other. Thus, monocyte migration from the bone 
marrow is facilitated by chemokines released from splenic Ly6Chi monocytes as part of an 
inflammatory response; in contrast, local cell division by remaining RPMs is a macrophage-
specific response; though the exact signal is not clear. Both are likely capable of repopulating 
the spleen individually, which may be important from an evolutionary perspective. 
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CHAPTER 6: Altered immune response following transfusion 
 
RBC transfusions have been associated with adverse effects, such as an increased risk 
of bacterial infection. In preparing RBCs for transfusion, donor RBCs are refrigerator stored for 
extended periods of time, during which time they undergo oxidative damage, ultimately leading 
to their rapid post-transfusion clearance from the circulation. We previously found that 
substantial erythrophagocytosis of transfused storage-damaged (i.e., “old”) RBCs induces 
ferroptosis in murine splenic RPMs, generating toxic lipid peroxides due to the iron internalized 
by these cells. This is accompanied by an inflammatory response involving chemokine 
expression by splenic Ly6Chi monocytes and monocyte trafficking to the spleen. However, the 
effects on the overall functioning of the splenic Ly6Chi monocytes and remaining RPMs are 
unclear, especially their responses to subsequent immune challenges. In a mouse model of 
RBC storage and transfusion, we found that, following a transfusion of old RBCs, macrophages 
were less capable of phagocytosing a subsequent particle stimulus, such as bacteria (i.e., E. 
coli and S. aureus) or additional old RBCs. However, splenic Ly6Chi monocytes became 
activated in a specific timeframe following the initial old RBC transfusion, thereby increasing 
their phagocytic capacity. Nonetheless, despite contributions from activated splenic Ly6Chi 
monocytes, RPM function was indispensable for clearing S. aureus; this functional impairment 
may make the transfusion recipient susceptible to S. aureus sepsis. In conclusion, these effects 
on innate immunity may constitute part of the spectrum of transfusion-related 
immunomodulation.  
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Section 6.1: Introduction 
RBC transfusions are a very common therapeutic, used in multiple settings (e.g., 
trauma, surgery, and cancer). Despite their clear benefits, RBC transfusions are also associated 
with adverse effects, including an increased risk of bacterial infection in recipients.(254, 255, 
262–266, 327) According to the United States FDA, human donor RBCs can be refrigerator-
stored for up to 42 days. During the storage process, RBCs undergo multiple structural and 
metabolic alterations, collectively known as “the storage lesion.”(274–277) As a result, up to 
25% of the storage-damaged RBCs are rapidly cleared from the circulation post-transfusion. 
Studies in murine models suggest that this process is predominantly mediated by macrophages 
in the liver and spleen (i.e., “extravascular hemolysis”).(129, 328)  
Pathologic erythrophagocytosis is associated with exacerbations of certain bacterial 
infections in mouse models, including E. coli,(247) S. aureus,(267, 329) and S. 
typhimurium.(247) Furthermore, patients with hemolytic disorders (e.g., sickle cell anemia) are 
more susceptible to certain infections.(268, 330) Extravascular hemolysis could increase 
susceptibility to infection by several possible mechanisms. These include, but are not limited to, 
increased iron levels in the circulation due to erythrophagocytosis(331) leading to impaired 
nutritional immunity,(332) changes in cytokine responses,(129) and phagocyte cell death after 
RBC ingestion.(292, 328) We previously found that substantial erythrophagocytosis of 
transfused storage-damaged (i.e., “old”) RBCs induces ferroptosis in murine RPMs, by 
generating toxic lipid peroxides due to the excessive iron internalized by these cells.(328) This 
is accompanied by an inflammatory response involving chemokine expression by splenic Ly6Chi 
monocytes and monocyte trafficking to the spleen. However, the effects on the overall 
functioning of the remaining macrophages remain unclear, especially in the context of their 
capacity to respond to subsequent immune challenges. Thus, depletion of this crucial splenic 
phagocyte population could impair the host’s ability to respond to subsequent bacterial 
infections and RBC transfusions. Therefore, we aimed to determine whether an initial 
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transfusion of stored RBCs influences the response to either subsequent bacteremia or old RBC 
transfusion. 
To investigate the impact of a prior transfusion of old RBCs on subsequent responses to 
clinically-relevant stimuli, we used a mouse model of RBC storage and transfusion.(278) We 
also incorporated a mouse model of bacterial sepsis with S. aureus or E. coli, which commonly 
cause Gram-positive and Gram-negative sepsis in humans, respectively.(333, 334) In this 
model, following a transfusion of old RBCs, macrophages were less capable of phagocytosing a 
subsequent particle stimulus, such as bacteria or additional old RBCs, and splenic Ly6Chi 
monocytes became activated in a specific timeframe following the initial old RBC transfusion. 
Nonetheless, despite the contributions from activated splenic Ly6Chi monocytes, RPM function 
was indispensable for clearing S. aureus. Given this impairment, an old RBC transfusion may 
open a window of susceptibility to S. aureus sepsis by altering the phagocyte response to 
subsequent immunologically-relevant stimuli. These effects on innate immunity may constitute 
part of the spectrum of transfusion-related immunomodulation (TRIM). 
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Section 6.2: Results 
An initial erythrophagocytosis event in vitro impairs subsequent phagocytosis of RBCs, 
E. coli, or S. aureus  
To determine whether erythrophagocytosis impacted the ability of macrophages to 
phagocytose subsequent stimuli, we first utilized an in vitro system. Thus, BMDMs that ingested 
opsonized RBCs (IgG-coated RBCs) (Fig 6.1A) exhibited impaired phagocytosis when 
incubated at a later time with additional IgG-coated RBCs, or with non-opsonized E. coli or S. 
aureus (Fig 6.1B-D). Washed IgG-coated RBCs were included to determine if soluble, non-
adherent IgG antibodies contributed to changes in phagocytosis. As such, using washed RBCs, 
we were able to observe a decrease in phagocytosis of S. aureus that was not observed without 
removing the excess, unbound IgG from the sample of IgG-coated RBCs. This may be due to 
excess soluble IgG binding to the surface of S. aureus, thereby engaging Fc-gamma receptors 
on macrophages to enhance phagocytosis.(26–28) This was compared to incubation with 
various controls that included PBS and fresh non-opsonized RBCs, the latter of which were not 
ingested by macrophages. The same observation was made using J774 murine macrophages; 
these exhibited decreased phagocytosis of IgG-coated RBCs, and of non-opsonized E. coli or 




Figure 6.1: An initial erythrophagocytosis event in vitro impairs subsequent 
phagocytosis of IgG-coated RBCs, S. aureus, and E. coli by macrophages  
(A) BMDMs were incubated with PBS, or with fluorescently-labeled (CellTrace Far Red) 
fresh RBCs, IgG-coated RBCs, or washed IgG-coated RBCs (with excess free IgG removed), 
and the percentage of macrophages that have undergone erythrophagocytosis was determined 
by flow cytometry. Following this initial incubation, BMDMs were incubated with additional 
fluorescently-labeled (FITC) (B) IgG-coated RBCs, (C) S. aureus, or (D) E. coli, and the 
percentage of BMDMs that had ingested these RBCs or bacteria, respectively, was quantified. 
(E) J774 cells were incubated with PBS, or with fluorescently-labeled fresh RBCs, IgG-coated 
RBCs, or washed IgG-coated RBCs, and erythrophagocytosis was determined by flow 
cytometry. Following this initial incubation, J774 cells were incubated with additional 
fluorescently-labeled (F) IgG-coated RBCs, (G) S. aureus, or (H) E. coli, and the percentage of 
J774 cells that had ingested these RBCs or bacteria, respectively, was quantified. Data are 
representative of at least 3 experiments, with 4 samples per group. ns, not significant; *, P<0.05; 
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An initial phagocytosis event in vivo, involving transfused old RBCs, impairs 
phagocytosis of subsequently transfused old RBCs or intravenously infused S. aureus, 
but not E. coli 
Packed, leukoreduced RBCs were prepared from wild-type C57BL/6 donor mice and 
used “fresh” or after 12-14 days of storage (i.e., “old”) under conditions that mimic those in 
clinical blood banks. At 30 minutes, 5 hours, and 2 days post-transfusion with fresh RBCs or old 
RBCs (or PBS infusion), mice were transfused again with old RBCs (Fig 6.2A-C). At 30 minutes 
and 5 hours post-transfusion, RPMs (VCAM-1+, F4/80hi, CD11blo), which are the predominant 
splenic population responsible for clearing old RBCs at these time points,(13) exhibited 
decreased clearance of a subsequent transfusion of old RBCs (51.8% to 23.5% and 48.9% to 
17.9%, respectively; Fig 6.2B, C). However, no differences were observed at 2 days after the 
initial transfusion, which correlates with prior findings that no significant ongoing clearance of 
circulating old RBCs by RPMs occurs at that time point.(13) Mice infused with PBS or 
transfused with old RBCs were then infected with S. aureus intravenously to model sepsis; this 
allowed us to determine if this initial erythrophagocytosis event would impair subsequent 
bacterial phagocytosis by RPMs (Fig 6.2D). At 30 minutes and 5 hours after an old RBC 
transfusion, there were substantial decreases in phagocytosis of S. aureus (10.4% to 5.9% and 
10.1% to 4.8%, respectively; Fig 6.2B, E). However, when mice were intravenously infected with 
E. coli following an initial transfusion of old RBCs, no statistically significant differences were 
observed between the level of bacterial phagocytosis at 30 minutes and 5 hours post-




Figure 6.2: An initial phagocytosis event in vivo involving transfused old RBCs impairs 
phagocytosis by RPMs of a subsequent transfusion of old RBCs or an infusion of S. 
aureus, but not of an infusion of E. coli 
Wild-type C57BL/6 mice were initially infused with 350 μl of PBS or transfused with 350 
μl of old RBCs. (A) At indicated time points, mice were given a subsequent transfusion of old 
























































































































































































strategy is shown for identifying RPMs (F4/80hi, CD11blo, VCAM-1+) and determining the 
percentage of RPMs that had ingested old RBCs or S. aureus. (C) The data were summarized 
as changes in phagocytosis following a second transfusion of old RBCs. For the remaining 
panels, wild-type C57BL/6 mice were initially infused with 350 μl of PBS or transfused with 350 
μl of fresh or old RBCs. (D) At indicated time points, mice were infused intravenously with S. 
aureus or E. coli. Changes are shown for phagocytosis of (E) S. aureus and (F) E. coli after 
receiving an initial transfusion of old RBCs. Data are representative of at least 3 independent 




Ly6Chi monocytes become activated and exhibit increased phagocytosis following an 
initial erythrophagocytosis event in vivo involving transfused old RBCs 
We previously found that splenic Ly6Chi inflammatory monocytes ingest transfused old 
RBCs and help mediate an inflammatory response following this transfusion. Therefore, we 
examined whether a prior erythrophagocytosis event by splenic Ly6Chi monocytes alters their 
subsequent ability to phagocytose clinically-relevant particles. Interestingly, at 5 hours post-
transfusion, splenic Ly6Chi monocytes exhibited a dramatic increase in the phagocytosis of old 
RBCs (2.4% to 7.8%; Fig 6.3A, B). The same trend was observed with a subsequent 
intravenous infection with S. aureus (14.0% to 37.2%; Fig. 6.3A, C) and E. coli (13.1% to 30.9%; 
Fig 6.3D).  
 In addition to increased phagocytosis, Ly6Chi monocytes also enhanced their surface 
expression of CD11b, indicating activation (Fig 6.4A). Due to our findings that splenic Ly6Chi 
monocytes increased their phagocytosis of S. aureus and became activated following a 
transfusion of old RBCs, we examined the effect of a prior transfusion of old RBCs on gene 
expression in the context of a systemic S. aureus infection. To this end, mice were infused with 
PBS or transfused with old RBCs, and 5 hours later they were infected intravenously with S. 
aureus. Splenic Ly6Chi monocytes were isolated and their gene expression profiles were found 
to cluster independently (Fig 6.4B). Splenic Ly6Chi monocytes that experienced a transfusion of 
old RBCs exhibited increased expression of Hmox1, Spic, Fth1, and Ftl1 (Fig 6.4C), as 
expected. Interestingly, a statistically significant change in expression of Slc40a1, the gene 
coding ferroportin, was not observed. Ferroportin is the only known iron exporter and plays an 
essential role in overall iron homeostasis.(30, 31) This finding could be due to additional 
regulation of ferroportin in response to bacterial infection.(32, 33)  
Additionally, genes associated with pathways involved in inflammatory responses, 
cellular responses to bacteria, and phagocytosis also increased (Fig 6.4D); this suggests that a 
prior transfusion of old RBCs may prime splenic Ly6Chi monocytes to respond to subsequent 
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stimuli. By examining specific genes known to be involved in immune responses to S. aureus 
infection, we found that genes relevant for inflammation and TLR signaling were upregulated 
(Fig 6.4E,F). For example, expression of Nod2, which plays a role in the innate immune 
response and can detect peptidoglycan from Gram-positive bacteria,(34) was increased. In 
addition, TLR2, which recognizes peptidoglycan and lipoteichoic acid from Staphyloccocus,(35) 
and is an important pattern recognition receptor for pathogens and microbes, was upregulated 
along with its adapter, MyD88.(36) Finally, various pro-inflammatory cytokines that are important 
for the innate immune response to S. aureus infection were also upregulated in mice that had 
received a transfusion of old RBCs prior to infection; these included IL-6 and IL-1β.(37) In 
contrast, multiple genes important for the immune response to infection were also 
downregulated, including Nos3 and Lyz1, which help generate nitric oxide species and form the 




Figure 6.3: Ly6Chi monocytes become activated and exhibit increased phagocytosis 
following an initial erythrophagocytosis event in vivo involving the transfusion of old 
RBCs 
Wild-type C57BL/6 mice were initially infused with 350 μl of PBS or transfused with 350 
μl of old RBCs. At indicated time points mice were given a subsequent transfusion of old RBCs, 
or an intravenous infusion of S. aureus or E. coli. (A) Flow cytometry gating strategy for 
identifying Ly6Chi monocytes (Ly6Chi, CD11bhi, CD115+, Ly6G-) and determining phagocytosis of 
old RBCs or S. aureus. The data are summarized as changes in phagocytosis of (B) a second 
transfusion of old RBCs, or (C) an intravenous infusion of S. aureus or (D) E. coli. Data are 
representative of at least 3 independent experiments. ns, not significant; **, P < 0.01; ****, P < 
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Figure 6.4: Ly6Chi monocytes become activated and alter their gene expression in 
response to S. aureus infection following a transfusion of old RBCs  
Wild-type C57BL/6 mice were initially infused with 350 μl of PBS or transfused with 350 
μl of old RBCs. (A) At the indicated time points, CD11b surface expression was quantified. Wild-
type C57BL/6 mice were initially infused with 350 μl of PBS or transfused with 350 μl of old 
RBCs. At 5 hours post-transfusion, splenic Ly6Chi monocytes were isolated by flow sorting from 
mice that were infused with PBS or transfused with fresh or old RBCs. (B) Principal component 
analysis comparing Ly6Chi monocytes from mice that received S. aureus and PBS with mice 
with mice that received S. aureus and old RBCs. (C) Gene expression analysis for selected 
genes involved in iron metabolism. (D) List of GO pathways upregulated in Ly6Chi monocytes 
from mice that received a transfusion of old RBCs prior to infection with S. aureus, relative to 
Ly6Chi monocytes from mice that received a PBS infusion prior to infection with S. aureus. A list 
of genes involved in the immune response found to be (E) upregulated in Ly6Chi monocytes 
from mice that received transfusion of old RBCs prior to infection with S. aureus. (F) A heat map 
depicting changes in the expression of genes involved in the immune response found to be 
upregulated or downregulated in Ly6Chi monocytes from mice that did or did not receive a 
transfusion of old RBCs prior to infection with S. aureus. A list of genes involved in the immune 
response found to be (G) downregulated in Ly6Chi monocytes from mice that received 
transfusion of old RBCs prior to infection with S. aureus. *, P<0.05; **, P<0.01; ***, P<0.001; 




A prior transfusion of old RBCs impairs the recipient’s ability to clear a subsequent 
transfusion of old RBCs or a subsequent systemic S. aureus infection 
 Given that we observed a post-transfusion decrease in phagocytosis by macrophages 
and an increase in phagocytosis by splenic Ly6Chi monocytes, we examined the effect of an 
initial erythrophagocytosis event on overall RBC recovery following a subsequent transfusion. 
To this end, we quantified post-transfusion RBC recovery for old RBCs that were transfused at 
various times following an initial transfusion. Interestingly, RBC clearance was slightly impaired 
in mice that received a transfusion of old RBCs 30 minutes previously (Fig 6.5A). However, no 
differences were observed when the initial transfusion was 5 hours or 2 days prior to the 
subsequent one (Fig 6.5A). Therefore, it is likely that the added contribution to RBC clearance 
by the primed splenic Ly6Chi monocytes at 5 hours post-transfusion restored overall RBC 
clearance.  
To determine the effects of prior transfusion of old RBCs on a model of S. aureus sepsis, 
luciferase-expressing S. aureus were infused intravenously into mice that had either been 
infused with PBS or transfused with old RBCs 5 hours previously. In prior studies, RPMs were 
dramatically depleted at 5 hours after an old RBC transfusion,(13) and the remaining RPMs 
exhibited decreased phagocytosis of S. aureus. Based on this change in an important splenic 
phagocyte population, it is possible that there could be an impaired immune response to 
bacterial infection. However, at 5 hours post-transfusion of old RBCs, splenic Ly6Chi monocytes 
become activated (Fig 6.4) and increase their phagocytosis of bacteria. With the simultaneous 
changes in these two populations, we examined how this would affect a systemic S. aureus 
infection. To this end, using in vivo imaging, we observed an increase in bacterial dissemination 
in mice that had received a transfusion of old RBCs 5 hours previously, leading to increased 
mortality (Fig 6.6A, B). This suggests that although splenic Ly6Chi monocytes exhibit increased 





Figure 6.5: An initial erythrophagocytosis event in vivo involving the transfusion of old 
RBCs leads to improved circulatory survival of subsequently transfused old RBCs 
Wild-type C57BL/6 mice were initially infused with 350 μl of PBS or transfused with 350 
μl of old RBCs. At indicated time points, mice were given a subsequent transfusion of old RBCs 
and the post-transfusion RBC recovery was determined. Data are representative of 3 






































































































Figure 6.6: An initial erythrophagocytosis event in vivo involving the transfusion of old 
RBCs leads to impaired clearance of a systemic S. aureus infection 
Wild-type C57BL/6 mice received an infusion of PBS or a transfusion of old RBCs, and 5 
hours later the mice were administered S. aureus intravenously. Bacterial dissemination was 
determined by in vivo imaging (A) and (B) quantified. Data are representative of at least 2 










































Section 6.3: Discussion 
Our results suggest that transfusions of old RBCs can alter the innate immune response, 
notably the responses of select populations of splenic macrophages and monocytes, to 
subsequent “ingestible” stimuli. RPMs and splenic Ly6Chi monocytes both contribute to the 
clearance of transfused storage-damaged, old RBCs, with RPMs exhibiting substantially more 
erythrophagocytosis and playing a significant role in iron recycling. In experiments in vitro using 
J774 macrophages and BMDMs, an initial erythrophagocytosis event involving opsonized RBCs 
dramatically reduced subsequent phagocytosis of E. coli, S. aureus, and IgG-coated RBCs by 
these macrophages.  
To investigate this effect in vivo, we used our mouse model of old RBC transfusion and 
clearance in which wild-type C57BL/6 mice were infused with PBS, or transfused with fresh (i.e., 
<24 hr after collection), or 12-14-day stored (“old”) RBCs. At various time points after this initial 
transfusion, mice were either infected with E. coli or S. aureus, or were transfused again with 
stored RBCs to examine the effects of the initial robust erythrophagocytosis event on 
subsequent phagocytosis. Following an initial transfusion of old RBCs, the remaining RPMs 
immediately exhibited decreased phagocytosis of S. aureus and additional old RBCs. However, 
by 5 hours post-transfusion, the splenic Ly6Chi monocyte population became activated, with 
increased surface expression of CD11b, and increased expression of various genes involved in 
regulating the immune response to infection. This was accompanied by dramatically increased 
phagocytosis of E. coli, S. aureus, and old RBCs. As a result, at 5 hours after the initial 
transfusion, RBC recovery of a subsequent transfusion of old RBCs did not change significantly, 
possibly due to compensation by the activated Ly6Chi monocytes. However, in vivo imaging 
studies, using luciferase-expressing bacteria, showed that, even with increased phagocytosis by 
Ly6Chi monocytes, these mice were less able to clear a “total-body” S. aureus infection. As 
such, the total systemic bacterial load significantly increased in mice that received an initial 
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transfusion of old RBCs, which was accompanied by decreased survival by 24 hours post-
transfusion, relative to the control mice that received PBS prior to infection.  
Taken together, these results suggest that, following a transfusion of old RBCs, splenic 
RPMs are less capable of phagocytosing bacteria or additional old RBCs, and that splenic 
Ly6Chi monocytes become activated in a specific timeframe following the initial old RBC 
transfusion. However, despite the contributions from activated splenic Ly6Chi monocytes, it 
appears that RPM function is indispensable for clearing S. aureus and that this is impaired 
following an old RBC transfusion, possibly providing a window of increased susceptibility to S. 
aureus sepsis following transfusions of old RBCs. In addition, it is important to consider that 
increased phagocytosis by Ly6Chi monocytes does not necessarily indicate an increased 
capacity to kill S. aureus. For example, gene expression analysis revealed that certain genes 
important for killing internalized bacteria, including Lyz1 and Nos3, were downregulated in mice 
that received a transfusion of old RBCs. Lyz1 encodes lysozyme 1, a bactericidal protein 
capable of causing bacterial cell lysis by cleaving the glycosidic linkage between N-acetyl 
glucosamine and N-acetyl muramic acid in cell-wall peptidoglycan.(38) Nos3 encodes nitric 
oxide synthase 3, which produces antimicrobial nitric oxide. Therefore, although these 
monocytes are activated, their effectiveness in killing internalized bacteria following transfusions 
of old RBCs may be compromised; this is yet to be determined. 
Nonetheless, it is important to note that, although our studies focused on RPMs and their 
impaired ability to phagocytose particles following erythrophagocytosis, there are other splenic 
macrophage subsets that may be relevant for clearing bacterial infections. For example, 
marginal zone and metallophilic macrophages were reported to phagocytose S. aureus and E. 
coli.(39) Additionally, neutrophils are an important cell population involved in clearing S. aureus 
and E. coli.(40, 41) However, neutrophils did not participate in the phagocytosis of transfused 
old RBCs in our model.(13) 
	 129 
Taken together, the phenomena described herein may underlie various aspects of 
TRIM.(42) Thus, given the decrease in phagocytosis of bacteria and RBCs by macrophages 
that have previously experienced a substantial erythrophagocytosis event, RBC transfusions 
could have immunosuppressive consequences affecting their responses to subsequent stimuli. 
In the acute setting, impaired clearance by macrophages due to erythrophagocytosis-mediated 
cell death could potentially impair protection against invading blood-borne pathogens.  
Additionally, erythrophagocytosis can impair the oxidative burst function of host 
cells,(43) which is used for bacterial killing. Therefore, we believe that the data presented here 
suggest that an acute window of susceptibility may exist following a transfusion of old RBCs. 
Finally, we believe that the mechanism described herein differs from the one we previously 
described regarding non-transferrin-bound iron’s effects on nutritional immunity; in that setting, 
acute rises in non-transferrin-bound iron levels following old RBC transfusion exacerbated an 
ongoing bacterial infection.(15) Nonetheless, by 5 hours post-transfusion, these levels are 
already decreasing back to baseline. Thus, effects on both nutritional immunity and innate 
immunity may underlie, at least some of, the pathophysiological consequences of TRIM.(42)   
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CHAPTER 7: Conclusion and Future Directions 
Adapted and expanded significantly from: Youssef LA, Spitalnik SL. Transfusion-related 
immunomodulation: a reappraisal Curr Opin Hematol. 2017 Nov;24(6):551-557. 
 
The overarching aims of this project are to investigate the overall effect of robust 
phagocytosis of storage-damaged (“old”) RBCs on the mononuclear phagocyte system and to 
determine whether robust erythrophagocytosis by mononuclear phagocytes impairs their 
subsequent clearance of bacterial infections. Using our mouse model, we found that RPMs 
were the predominant splenic population responsible for ingesting old, transfused RBCs. 
Following this enhanced erythrophagocytosis, RPMs underwent ferroptosis, with dramatic 
decreases observed in their cell numbers, accompanied by increases in ROS, lipid peroxidation, 
and PTGS2 gene expression in these cells (Figure 7.1).  
Old RBC transfusions also induced what appeared to be an RPM-dependent expression 
of CCL2 and CCL7 by splenic Ly6Chi monocytes, which was accompanied by emigration of 
inflammatory monocytes from the bone marrow into the circulation and then homing to the 
spleen. At least a portion of this influx of Ly6Chi monocytes remained in the spleen and 
differentiated into RPMs, thereby helping to restore the depleted RPM population. Together with 
local cell division among the raining RPMS, Ly6Chi monocytes help participate in a coordinated 
effort to return the splenic macrophage population back to steady-state levels.  
To date, ferroptosis has been described in cancer cells (297), kidney tubule cells (306, 
310, 311), fibroblasts (310, 312), neurons (313), and T cells (314). Based on these results, 
increased erythrophagocytosis is able to cause ferroptosis in macrophages, likely due to iron 
overload in the macrophages and a subsequent antioxidant response that is insufficient to 
handle the dramatic increase in iron. As macrophages play important physiological roles in iron 
metabolism and recycling, the occurrence of ferroptosis in these cells is especially relevant. 
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Normal physiological RBC and iron recycling, where each macrophage clears, on average, one 
RBC per day, does not appear to have any adverse effects on macrophage function.  
Given the importance of macrophages in host defense, the observed adverse effects of 
increased erythrophagocytosis hold substantial clinical relevance. Increased prevalence of 
certain bacterial infections in humans with hemolytic disorders, such as in sickle cell disease 
(316) and malaria (317), have been observed in various studies. Because an increased 
incidence of infection following transfusions can exemplify TRIM (315), it is legitimate to 
postulate whether the effects on RPM cell number seen here represent at least one mechanism 
underlying TRIM.  
Using our mouse model of transfusion, we found that transfusions of old RBCs can alter 
the response of select populations of splenic macrophages and monocytes to subsequent 
“ingestible” stimuli. RPMs and splenic Ly6Chi monocytes both contribute to clearing transfused 
storage-damaged, old RBCs, with RPMs exhibiting substantially more erythrophagocytosis and 
playing a significant role in iron recycling. Following this erythrophagocytosis, macrophages (in 
vivo and in vitro), demonstrated a significant decrease in their capacity to phagocytose S. 
aureus, E. coli, and RBCs (old and IgG-coated). Conversely, we observed the opposite effect 
with Ly6Chi monocytes. Ly6Chi monocytes actually increased their phagocytosis of S. aureus, E. 
coli, and old RBCs by 5 hours post-transfusion. This, combined with gene expression analysis 
and surface expression of CD11b, suggest that this splenic population of monocytes becomes 
activated during this particular time frame. As a result, at 5 hours after the initial transfusion, 
RBC recovery of a subsequent transfusion of old RBCs did not change significantly, possibly 
due to compensation by the activated Ly6Chi monocytes. However, despite this added 
contribution from the Ly6Chi monocytes, mice that were infected with S. aureus were less able 
to clear the systemic bacterial infection and exhibited decreased survival.  
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Taken together, the phenomena described herein may underlie various aspects of TRIM, 
with old RBC transfusions having potential immunosuppressive consequences that effect the 
response to subsequent stimuli.(315) The overall concept of TRIM, however, can be very broad 
as it relates to the impact that transfusions can have on the immune system. The effects of 
various stimuli have the potential to lead to immediate and long-term effects. The experiments 
discussed here focused on the more immediate impact that increased erythrophagocytosis due 
to transfusions of old RBCs have. However, going forward, it will be useful to investigate the 
“immunosuppressive” effects that “pure” RBC transfusions may have on specific aspects of the 
innate immune system at various time post-transfusion beyond acute effects to also include 
subacute (i.e., intermediate) and chronic (i.e., long-term) categories. 
In the acute phase, the initial interaction between the innate immune system and 
storage-damaged, transfused RBCs involves phagocytosis, primarily by macrophages, but also 
by monocytes and, to a much lesser extent, by DCs and granulocytes in mouse models of 
transfused storage-damaged RBC clearance. Erythrophagocytosis, followed by lysosomal 
catabolism of the ingested RBCs, can rapidly produce non-transferrin-bound iron (129, 134, 
335), induce the release of specific cytokines (129), inhibit subsequent macrophage function, 
and damage lysosomes, potentially leading to cell death (336, 337). In this context, macrophage 
cell death may have an “immunosuppressive” effect on innate immunity by decreasing the 
number of available phagocytes. However, robust erythrophagocytosis can also promote an 
inflammatory response with increased expression of circulating cytokines.(129) In addition, non-
transferrin-bound iron, in the context of nutritional immunity, could enhance pathogen 
virulence.(136) Taken together, these outcomes could produce a TRIM effect of enhancing 
postsurgical or nosocomial bacterial infection rates and severity.(338) In addition, ingestion of 
(antibody coated) RBCs by splenic granulocytes (339) can impair oxidative-burst function (337), 
thereby potentially impairing this type of protection against invading blood-borne pathogens. 
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 In the subacute setting, macrophages exhibit substantial plasticity and diversity, enabling 
them to change their phenotype rapidly in response to select stimuli. Several macrophage 
polarization states have been described that extend beyond the M1 and M2 distinctions, 
characteristically reserved for “classically” or “alternatively” activated macrophages, 
respectively. These include other subgroups (281, 340) in response to additional stimuli, such 
as to oxidized phospholipids (i.e., Mox) (341, 342), and Chemokine (C-X-C motif) Ligand 4 (i.e., 
M4) (221, 222). One polarization state that may be particularly relevant to TRIM is Mhem, which 
arises from macrophage stimulation by heme and Hb. Though currently primarily studied in 
atherosclerotic plaques, Mhem macrophages are defined by increased HO-1 expression 
accompanied by anti-inflammatory phenotypic properties (343–346). All of these various 
polarization states are intimately interrelated to particular metabolic pathways (i.e., 
“immunometabolism”) (347, 348), and it is conceivable that erythrophagocytosis can induce 
changes in the functional polarization of the ingesting macrophage and/or its neighboring cells 
(349). The duration of these effects can vary and could affect subsequent responses to 
exposure to pathogens or transfused RBCs, or affect the immune surveillance of neoplastic 
cells. 
An additional concept relating to monocyte and macrophage functional plasticity has 
been discovered recently; that is, these key players in the innate immune system can exhibit 
“memory,” a characteristic previously thought to be limited to lymphocytes involved in adaptive 
immunity. To this end, in the chronic setting, monocytes and macrophages that are exposed to 
certain stimuli can develop metabolic and epigenetic changes that lead to long-term alterations 
in subsequent responses by these cells. To highlight their versatility further, the memory 
established in monocytes and macrophages can be stimulatory or suppressive, with both effects 
often occurring simultaneously, depending on which genes are expressed or suppressed.(350) 
The process of macrophage “priming” or “training” occurs when prior exposure to a specific 
stimulus induces an enhanced immune response, such as increased microbicidal activity (i.e., 
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increased phagocytic activity and increased expression of proinflammatory genes).(351) As 
examples, stimuli that trigger priming can include phagocytosis of apoptotic cells (352), 
ingestion of ß-glucan (present in the Candida cell wall) (353), or exposure to lipopolysaccharide 
(LPS) (354). In addition to altering gene expression, these stimuli can induce changes in 
metabolic function, such as triggering macrophages to switch to glucose metabolism to increase 
energy production for supporting increased cellular activation.(355) In contrast, “tolerance” or 
“immmunoparalysis” occurs when prior exposure of macrophages to a specific stimulus results 
in decreased responses to subsequent exposures to that stimulus or similar stimuli; LPS is the 
most studied example of such a tolerizing response in macrophages.(353) Interestingly, these 
memory-inducing events can also interact with each other; for example, “priming” exposure to 
fungal ß-glucan can reverse the tolerizing effects of LPS-induced immunoparalysis.(356) 
The stimuli to which monocytes or macrophages are exposed can widely vary based on 
their location within an organism. In the context of possible RBC transfusion-mediated metabolic 
reprograming, splenic RPMs and hepatic Kupffer cells are likely targets, given their 
physiological roles in erythrophagocytosis and iron recycling. For example, enhancer 
landscapes of murine splenic macrophages and Kupffer cells were found to cluster together, 
presumably because they share similar microenvironments with substantial physiological 
exposure to senescent RBCs.(199) In this context, the contents of RBCs (e.g., heme, iron, and 
Hb) may function as tolerance-inducing stimuli. In pathological settings, such as the transfusion 
of storage-damaged RBCs or during IgG-mediated transfusion reactions, these cell types clear 
substantial amounts of RBCs in a relatively short period of time, which contrasts with their 
normal physiological roles. This suggests the testable hypothesis of whether pathologically 
increased erythrophagocytosis can “train” macrophages and monocytes. In the context of TRIM, 
one hypothesis would be whether increased erythrophagocytosis by macrophages or 
monocytes induces epigenetic and/or metabolic “immunosuppressive” alterations that affect 
their ability to function appropriately in response to subsequent stimuli, such as exposure to 
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invading pathogens (357), inflammatory disorders, surgery, trauma, or immune surveillance of 
neoplastic cells. In addition, it is possible that the effects on macrophages and monocytes may 
not only be mediated by the ingested RBCs per se, but also by the signal transduction pathways 
activated by the relevant cell surface receptor recognizing the “damaged” RBC (e.g., various Fc-
gamma receptors for IgG-opsonized RBCs). 
In summary, these studies have helped elucidate the impact that transfusions of old 
RBCs, which are accompanied by substantial erythrophagocytosis, have on the RPM 
population, as well as an accompanying inflammatory response. Future studies could help 
determine what these effects are beyond the context of an acute response that we studied a few 
hours after transfusion. Extending these studies to longer time periods and examining the 
macrophages and monocytes may lead to understanding any chronic effects that transfusions of 






Figure 7.1: Model for ferroptosis induced in macrophages and inflammatory response 
after a transfusion of old RBCs 
Macrophages undergo ferroptosis following increased erythrophagocytosis and are 
replaced by both circulating monocytes and local cell division. Transfusions of storage-damaged 
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